{"content":"<li class=\"n-box-item date-title\" data-end=\"1513054799\" data-start=\"1512968400\" data-txt=\"Monday, December 23, 2019\">Monday, December 11, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3317631\" data-ts=\"1513031779\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317631-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a> <font color='green'>+77.4%</font>. <a href='https://seekingalpha.com/symbol/KALA' title='Kala Pharmaceuticals'>KALA</a> <font color='green'>+6.9%</font>. <a href='https://seekingalpha.com/symbol/KMG' title='KMG Chemicals, Inc.'>KMG</a> <font color='green'>+6.0%</font>. <a href='https://seekingalpha.com/symbol/IRET' title='Investors Real Estate Trust'>IRET</a> <font color='green'>+5.9%</font>. <a href='https://seekingalpha.com/symbol/APTI' title='Apptio'>APTI</a> <font color='green'>+4.0%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> PPHM <font color='red'>-18.7%</font>. <a href='https://seekingalpha.com/symbol/CASY' title='Casey&#39;s General Stores, Inc.'>CASY</a> <font color='red'>-4.0%</font>. <a href='https://seekingalpha.com/symbol/NCS' title='NCI Building Systems Inc.'>NCS</a> <font color='red'>-2.9%</font>. <a href='https://seekingalpha.com/symbol/ZAGG' title='ZAGG Inc'>ZAGG</a> <font color='red'>-2.5%</font>. <a href='https://seekingalpha.com/symbol/OAS' title='Oasis Petroleum Inc.'>OAS</a> <font color='red'>-2.5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317631\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$PTI $KALA $KMG - After Hours Gainers / Losers https://seekingalpha.com/news/3317631-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3317631-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317630\" data-ts=\"1513031550\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IRM\" target=\"_blank\">IRM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317630-iron-mountain-to-buy-u-s-operations-of-io-data-centers-for-1_32b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Iron Mountain to buy U.S. operations of IO Data Centers for $1.32B</a></h4><ul>     <li>Iron Mountain (NYSE:<a href='https://seekingalpha.com/symbol/IRM' title='Iron Mountain Inc.'>IRM</a>)&nbsp;<font color='red'>-1.7%</font> after-hours on news it <a href=\"https://seekingalpha.com/pr/17023849-iron-mountain-acquire-io-data-centers-u-s-operations-approximately-1_3-billion\" target=\"_blank\">agrees to acquire</a> the U.S. operations of colocation data center services provider IO Data Centers for ~$1.32B including four data centers in Arizona, New Jersey and Ohio.</li>     <li>The agreement, combined with the acquisition of FORTRUST data center in September and its international data center expansion through the planned acquisition of two Credit  Suisse data centers in the London and Singapore markets, would raise IRM's data center portfolio to more than 90 MW  of existing capacity, with an additional 26 MW of capacity currently under construction and planned and future expansion potential of another 135 MW.</li><li>To help fund the deal, IRM commences a <a href=\"https://seekingalpha.com/pr/17023854-iron-mountain-incorporated-launches-common-stock-offering\" target=\"_blank\">public offering</a> of 14.5M common shares, with an underwriters option to purchase up to an additional 2.175M shares.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317630\" data-linked=\"Iron Mountain to buy U.S. operations of IO Data Centers for $1.32B\" data-tweet=\"$IRM - Iron Mountain to buy U.S. operations of IO Data Centers for $1.32B https://seekingalpha.com/news/3317630-iron-mountain-to-buy-u-s-operations-of-io-data-centers-for-1_32b?source=tweet\" data-url=\"https://seekingalpha.com/news/3317630-iron-mountain-to-buy-u-s-operations-of-io-data-centers-for-1_32b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317614\" data-ts=\"1513028717\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGIO\" target=\"_blank\">AGIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317614-agios-pharmas-ivosidenib-shows-positive-effect-in-early-stage-aml-study-shares-ahead-3-after\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agios Pharma&#39;s ivosidenib shows positive effect in early-stage AML study; shares ahead 3% after hours</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17023731-new-data-ivosidenib-phase-1-dose-escalation-expansion-trial-demonstrate-durable-responses\" target=\"_blank\">Results </a>from a Phase 1 dose-escalation and expansion study assessing Agios Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/AGIO' title='Agios Pharmaceuticals, Inc.'>AGIO</a>) ivosidenib (AG-120) in patients with relapsed/refractory acute myeloid leukemia &#40;AML&#41; with a genetic mutation called IDH1 showed a treatment benefit. The data were presented at ASH in Atlanta.</li><li>In 125 patients who received a daily 500 mg dose of ivosidenib and were on treatment at least six months, the overall response rate &#40;ORR&#41; was 41.6% (n=52/125) with a 30.4% (n=38/125) partial hematologic recovery rate. The complete response rate was 21.6% (n=27/125).</li><li>On the safety front, the most common adverse events (AEs) in 258 treated patients were diarrhea (33.3%), elevated white blood cells (30.2%), nausea (29.5%), fatigue (28.7%) and febrile neutropenia (25.2%).</li><li>In the 125-subject group cited above, 8% of patients experienced serious elevated white blood cells (leukocytosis) which was managed with hydroxyurea. 8% experienced a serious heart arrhythmia called QT prolongation and 9.6% experienced IDH-differentiation syndrome, a reaction characterized by rapid increases in white blood cells, fever and difficulty breathing, which was controlled with corticosteroids and diuretics.</li><li>Orphan Drug- and Fast Track-tagged&nbsp;<a href=\"http://www.agios.com/pipeline/idh-program/\" target=\"_blank\">ivosidenib&nbsp;</a>is an orally available inhibitor of mutated IDH1 protein, a metabolic enzyme that is overexpressed in a range of cancers.</li><li>The company says it will file a U.S. marketing application this month. Management will host an investor event today at 8:00 pm ET to discuss the results.</li><li>Shares are up&nbsp;<font color='green'>3%</font>&nbsp;after hours on modest volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317614\" data-linked=\"Agios Pharma&#39;s ivosidenib shows positive effect in early-stage AML study; shares ahead 3% after hours\" data-tweet=\"$AGIO - Agios Pharma&#39;s ivosidenib shows positive effect in early-stage AML study; shares ahead 3% after hours https://seekingalpha.com/news/3317614-agios-pharmas-ivosidenib-shows-positive-effect-in-early-stage-aml-study-shares-ahead-3-after?source=tweet\" data-url=\"https://seekingalpha.com/news/3317614-agios-pharmas-ivosidenib-shows-positive-effect-in-early-stage-aml-study-shares-ahead-3-after\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317611\" data-ts=\"1513028443\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COUP\" target=\"_blank\">COUP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317611-coupa-software-acquires-cross-catalog-search-provider\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coupa Software acquires cross-catalog search provider</a></h4><ul>     <li>Coupa Software (NASDAQ:<a href='https://seekingalpha.com/symbol/COUP' title='Coupa Software Inc'>COUP</a>)&nbsp;<a href=\"https://seekingalpha.com/pr/17023829-coupa-acquires-simeno-amplify-open-marketplace-buying\" target=\"_blank\">acquires</a> Simeno, a provider of cross-catalog search and catalog management.</li><li>Coupa plans to use Simeno&rsquo;s tech to grow its Open Buy Program and to increase its local presence in German and Swiss markets.</li><li>No financial terms disclosed.</li><li>Coupa shares are&nbsp;<font color='red'>down 0.92%&nbsp;</font>aftermarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317611\" data-linked=\"Coupa Software acquires cross-catalog search provider\" data-tweet=\"$COUP - Coupa Software acquires cross-catalog search provider https://seekingalpha.com/news/3317611-coupa-software-acquires-cross-catalog-search-provider?source=tweet\" data-url=\"https://seekingalpha.com/news/3317611-coupa-software-acquires-cross-catalog-search-provider\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317605\" data-ts=\"1513027663\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OAS\" target=\"_blank\">OAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317605-oasis-petroleum-buys-20k-delaware-basin-acres-for-946m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oasis Petroleum buys 20K Delaware Basin acres for $946M</a></h4><ul>     <li>Oasis Petroleum (NYSE:<a href='https://seekingalpha.com/symbol/OAS' title='Oasis Petroleum Inc.'>OAS</a>) <font color='red'>-2.7%</font> after-hours as it <a href=\"https://seekingalpha.com/pr/17023758-oasis-petroleum-announces-delaware-basin-acquisition-provides-operational-updates\" target=\"_blank\">agrees to acquire</a> 20.3K acres in the Delaware Basin from Forge Energy for $946M in cash and stock.</li>     <li>OAS says the acreage contains 601 gross operated locations and 507 net core  locations targeting the Wolfcamp A, B, and C and the Bone Spring formations, with extensive additional upside from other intervals in the column; production on the acreage totaled 3,500 boe/day in November; it expects to drill 16-20 gross wells and complete 6-8 gross wells with a ~$100M capital program in 2018.</li>          <li>To help fund the deal, OAS commences a <a href=\"https://seekingalpha.com/pr/17023771-oasis-petroleum-inc-announces-public-offering-common-stock\" target=\"_blank\">public offering</a> of 32M common shares, with an underwriters option to purchase up to an additional 4.8M shares.</li>     <li>Overall, OAS says October production was ~70K boe/day and 72K in November, already surpassing its planned year-end exit rate, prompting it to raise guidance for Q4 production to 71K-73K boe/day from  its earlier outlook for 69K-72K.</li><li>Additionally, OAS says it expects to divest up to $500M in non-core Williston Basin acreage during 2018.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317605\" data-linked=\"Oasis Petroleum buys 20K Delaware Basin acres for $946M\" data-tweet=\"$OAS - Oasis Petroleum buys 20K Delaware Basin acres for $946M https://seekingalpha.com/news/3317605-oasis-petroleum-buys-20k-delaware-basin-acres-for-946m?source=tweet\" data-url=\"https://seekingalpha.com/news/3317605-oasis-petroleum-buys-20k-delaware-basin-acres-for-946m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317604\" data-ts=\"1513027438\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CASY\" target=\"_blank\">CASY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317604-caseys-general-stores-slips-after-soft-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Casey&#39;s General Stores slips after soft earnings</a></h4><ul>     <li>Casey's General Stores (NASDAQ:<a href='https://seekingalpha.com/symbol/CASY' title='Casey&#39;s General Stores, Inc.'>CASY</a>) slips in after-hours trading after the retailer fell short with its FQ2 report.</li>     <li>On the fuel side of the business, same-store gallons sold were up 1.9% with an average margin of&nbsp; $0.197 per gallon.</li>     <li>Retail same-store sales were up 2.5% with an average margin of 32.0%.</li><li>Full-year guidance from Casey's is for fuel same-store sales growth of 1% to 2% and grocery/merchandise same-store sales growth of 2% to 4%.</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3317596-caseys-general-stores-misses-0_12-misses-revenue\" target=\"_blank\">Caseys General Stores misses by $0.12, misses on revenue</a> (Dec. 11)</li><li>CASY&nbsp;<font color='red'>-0.62%</font>&nbsp;AH to $120.50.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317604\" data-linked=\"Casey&#39;s General Stores slips after soft earnings\" data-tweet=\"$CASY - Casey&#39;s General Stores slips after soft earnings https://seekingalpha.com/news/3317604-caseys-general-stores-slips-after-soft-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3317604-caseys-general-stores-slips-after-soft-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317595\" data-ts=\"1513026815\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VECO\" target=\"_blank\">VECO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317595-veeco-announces-100m-repurchase-program\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Veeco announces $100M repurchase program</a></h4><ul><li>Veeco Instruments&rsquo; (NASDAQ:<a href='https://seekingalpha.com/symbol/VECO' title='Veeco Instruments Inc.'>VECO</a>)&nbsp;board <a href=\"https://seekingalpha.com/pr/17023751-veeco-authorizes-100-million-share-repurchase-program\" target=\"_blank\">authorizes </a>the repurchase of up to $100M in common stock over the next two years.</li><li>Veeco shares are&nbsp;<font color='green'>up 1.6%</font>&nbsp;aftermarket.&nbsp; &nbsp;)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317595\" data-linked=\"Veeco announces $100M repurchase program\" data-tweet=\"$VECO - Veeco announces $100M repurchase program https://seekingalpha.com/news/3317595-veeco-announces-100m-repurchase-program?source=tweet\" data-url=\"https://seekingalpha.com/news/3317595-veeco-announces-100m-repurchase-program\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317594\" data-ts=\"1513026730\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPMC\" target=\"_blank\">BPMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317594-blueprint-readies-275m-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blueprint readies $275M stock offering</a></h4><ul><li>Blueprint Medicines (NASDAQ:<a href='https://seekingalpha.com/symbol/BPMC' title='Blueprint Medicines'>BPMC</a>) <a href=\"https://seekingalpha.com/pr/17023735-blueprint-medicines-announces-proposed-public-offering-shares-common-stock\" target=\"_blank\">launches </a>a $275M public offering of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317594\" data-linked=\"Blueprint readies $275M stock offering\" data-tweet=\"$BPMC - Blueprint readies $275M stock offering https://seekingalpha.com/news/3317594-blueprint-readies-275m-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3317594-blueprint-readies-275m-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317588\" data-ts=\"1513026379\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACER\" target=\"_blank\">ACER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317588-acer-therapeutics-readies-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acer Therapeutics readies equity offering</a></h4><ul><li>Acer Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ACER' title='Acer Therapeutics Inc.'>ACER</a>) <a href=\"https://seekingalpha.com/pr/17023739-acer-therapeutics-announces-proposed-underwritten-public-offering-common-stock\" target=\"_blank\">commences </a>a public offering of common stock. Price, volume and terms have yet to be released.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317588\" data-linked=\"Acer Therapeutics readies equity offering\" data-tweet=\"$ACER - Acer Therapeutics readies equity offering https://seekingalpha.com/news/3317588-acer-therapeutics-readies-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3317588-acer-therapeutics-readies-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317586\" data-ts=\"1513026199\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLUE\" target=\"_blank\">BLUE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317586-bluebird-bio-readies-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bluebird bio readies equity offering</a></h4><ul><li>Bluebird bio (NASDAQ:<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a>) <a href=\"https://seekingalpha.com/pr/17023733-bluebird-bio-announces-proposed-public-offering-common-stock\" target=\"_blank\">launches </a>a $600M public offering of common stock. Price, volume&nbsp; and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317586\" data-linked=\"Bluebird bio readies equity offering\" data-tweet=\"$BLUE - Bluebird bio readies equity offering https://seekingalpha.com/news/3317586-bluebird-bio-readies-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3317586-bluebird-bio-readies-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317582\" data-ts=\"1513025896\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRUB\" target=\"_blank\">GRUB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317582-grubhubplus-2_9-after-keybanc-boosts-price-target-to-match-street-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GrubHub +2.9% after KeyBanc boosts price target to match Street high</a></h4><ul>   <li>GrubHub (NYSE:<a href='https://seekingalpha.com/symbol/GRUB' title='GrubHub Inc.'>GRUB</a>) has <font color='green'>gained 2.9%</font> after a price-target boost from KeyBanc, which sees the company holding up under competitive pressure in the food-delivery space.</li>    <li>The firm raised its target to $80 -- 17% upside from yesterday's closing price.</li>    <li>\"<a href=\"https://www.marketwatch.com/story/grubhub-stock-rises-after-analyst-cites-easing-of-competitive-pressures-2017-12-11\" target=\"_blank\">Amazon's impact has quieted</a> relative to prior rounds of checks,\" says analyst Brad Erickson, and GrubHub is withstanding competition from UberEats as well.</li>    <li>There are also more possible acquisition targets for GrubHub that would be \"almost immediately accretive,\" he says, including meal-kit companies like Munchery and Gobble and other delivery firms like DoorDash.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317582\" data-linked=\"GrubHub +2.9% after KeyBanc boosts price target to match Street high\" data-tweet=\"$GRUB - GrubHub +2.9% after KeyBanc boosts price target to match Street high https://seekingalpha.com/news/3317582-grubhubplus-2_9-after-keybanc-boosts-price-target-to-match-street-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3317582-grubhubplus-2_9-after-keybanc-boosts-price-target-to-match-street-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317581\" data-ts=\"1513025810\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIVV\" target=\"_blank\">BIVV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317581-bioverativs-bivv009-shows-positive-effect-in-early-stage-study-in-rare-blood-disorder-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bioverativ&#39;s BIVV009 shows positive effect in early-stage study in rare blood disorder; shares ahead 3%</a></h4><ul><li>A Phase 1b clinical trial assessing Bioverativ's (<a href='https://seekingalpha.com/symbol/BIVV' title='Bioverativ Inc.'>BIVV</a> <font color='green'>+3%</font>) BIVV009 in patients with cold agglutinin disease (CAgD) showed a <a href=\"https://seekingalpha.com/pr/17023683-bioverativ-s-investigational-bivv009-demonstrates-safety-tolerability-efficacy-phase-1b\" target=\"_blank\">treatment effect</a> and favorable safety profile. The results were presented at ASH in Atlanta.</li><li>CAgD is an autoimmune disorder in which the body's immune system destroys red blood cells (hemolytic anemia).</li><li>Hemoglobin levels increased in 100% (n=6/6) of subjects eliminating the need for transfusions during the treatment period.</li><li>Maintenance therapy has shown a sustained response for more than 18 months, including the control of hemolysis.</li><li>On the safety front, 83% (n=5/6) of patients experienced at least one adverse event, none serious related to the study drug.</li><li>BIVV009 is a humanized monoclonal antibody designed to bind to an enzyme in the complement pathway called C1s which impacts the central mechanism of CAgD.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317581\" data-linked=\"Bioverativ&#39;s BIVV009 shows positive effect in early-stage study in rare blood disorder; shares ahead 3%\" data-tweet=\"$BIVV - Bioverativ&#39;s BIVV009 shows positive effect in early-stage study in rare blood disorder; shares ahead 3% https://seekingalpha.com/news/3317581-bioverativs-bivv009-shows-positive-effect-in-early-stage-study-in-rare-blood-disorder-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3317581-bioverativs-bivv009-shows-positive-effect-in-early-stage-study-in-rare-blood-disorder-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317580\" data-ts=\"1513025051\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XRX\" target=\"_blank\">XRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317580-icahn-calls-for-xerox-ceo-exit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Icahn calls for Xerox CEO exit</a></h4><ul>     <li>Carl Icahn calls for the&nbsp;<a href=\"https://twitter.com/CNBCnow/status/940320316689207296\" target=\"_blank\">removal</a> of Xerox (<a href='https://seekingalpha.com/symbol/XRX' title='Xerox Corporation'>XRX</a> <font color='red'>-0.3%</font>) CEO Jeff Jacobsen from his position in an interview with The Wall Street Journal.</li>     <li>Icahn ended a standstill agreement withe Xerox earlier today and nominated four directors to the board.</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3317405-icahn-looks-board-seats-xerox\" target=\"_blank\">Icahn looks for more board seats at Xerox</a> (Dec. 11)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317580\" data-linked=\"Icahn calls for Xerox CEO exit\" data-tweet=\"$XRX - Icahn calls for Xerox CEO exit https://seekingalpha.com/news/3317580-icahn-calls-for-xerox-ceo-exit?source=tweet\" data-url=\"https://seekingalpha.com/news/3317580-icahn-calls-for-xerox-ceo-exit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317579\" data-ts=\"1513025039\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VMI\" target=\"_blank\">VMI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317579-valmont-downgraded-stifel-on-outlook-for-lower-irrigation-revenues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Valmont downgraded at Stifel on outlook for lower irrigation revenues</a></h4><ul>     <li>Valmont Industries (<a href='https://seekingalpha.com/symbol/VMI' title='Valmont Industries, Inc.'>VMI</a> <font color='red'>-3.4%</font>) is lower after Stifel <a href=\"https://www.streetinsider.com/Analyst+PT+Change/Stifel+Downgrades+Valmont+Industries+%28VMI%29+to+Hold+Citing+Lowered+Estimates+for+20182019+On+Lower+Expected+Irrigation+Revenues/13586213.html\" target=\"_blank\">downgrades</a> shares to Hold from Buy with a $174 price target, trimmed from $177, and lowers its estimates for 2018 and 2019 primarily on lower expected irrigation revenue following its survey of VMI's dealers in October and competitor Lindsay's (<a href='https://seekingalpha.com/symbol/LNN' title='Lindsay Corporation'>LNN</a> <font color='red'>-0.6%</font>) dealers published last week.</li><li>The firm says it used a slightly higher multiple on the lower earnings to account for its belief that the secular outlook for irrigation is strong and that its 2019 estimate for irrigation now is further below normalized earnings.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317579\" data-linked=\"Valmont downgraded at Stifel on outlook for lower irrigation revenues\" data-tweet=\"$VMI $VMI $LNN - Valmont downgraded at Stifel on outlook for lower irrigation revenues https://seekingalpha.com/news/3317579-valmont-downgraded-stifel-on-outlook-for-lower-irrigation-revenues?source=tweet\" data-url=\"https://seekingalpha.com/news/3317579-valmont-downgraded-stifel-on-outlook-for-lower-irrigation-revenues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:43 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317576\" data-ts=\"1513024370\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GKOS\" target=\"_blank\">GKOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317576-glaukos-quick-dive-on-report-of-reduced-reimbursements\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Glaukos with quick dive on report of reduced reimbursements</a></h4><ul><li>via Bloomberg's Bailey Lipschultz</li><li>Cahaba Government Benefit Administrators has reduced Glaukos' (<a href='https://seekingalpha.com/symbol/GKOS' title='Glaukos'>GKOS</a> <font color='red'>-6.8%</font>) 2018 physician reimbursement rates, according&nbsp; to BMO's Joanne Wuensch.</li><li>Shares are&nbsp;<font color='red'>down 6.9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317576\" data-linked=\"Glaukos with quick dive on report of reduced reimbursements\" data-tweet=\"$GKOS - Glaukos with quick dive on report of reduced reimbursements https://seekingalpha.com/news/3317576-glaukos-quick-dive-on-report-of-reduced-reimbursements?source=tweet\" data-url=\"https://seekingalpha.com/news/3317576-glaukos-quick-dive-on-report-of-reduced-reimbursements\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317573\" data-ts=\"1513024050\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWX\" target=\"_blank\">TWX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317573-disneys-coco-outpunches-justice-league-for-third-week\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Disney&#39;s &#39;Coco&#39; outpunches &#39;Justice League&#39; for third week</a></h4><ul>   <li><i>Coco</i> (<a href=\"http://seekingalpha.com/symbol/DIS\" target=\"_blank\">DIS</a> <font color='green'>+2%</font>) held a solid lead at the box office for the third week in a row, topping <i>Justice League</i> (NYSE:<a href='https://seekingalpha.com/symbol/TWX' title='Time Warner Inc.'>TWX</a>) yet again and crossing over the $135M mark in domestic grosses.</li>    <li>The week had no notable newcomers, other than the wide release of A24's <i>The Disaster Artist,</i> which rode a healthy per-theater gross to $6.4M and the No. 4 spot, behind <i>Wonder</i> (<a href='https://seekingalpha.com/symbol/LGF.A' title='Lions Gate Entertainment Corp.'>LGF.A</a> <font color='red'>-0.5%</font>, <a href='https://seekingalpha.com/symbol/LGF.B' title='Lions Gate Entertainment Corp.'>LGF.B</a> <font color='red'>-0.5%</font>) with $8.45M.</li>    <li><i>Justice League's</i> $9.6M added to weekday totals to bring that film over $200M domestically -- a total of $212.1M, adding to a worldwide gross total of $613.4M.</li>    <li><i>Coco,</i> meanwhile, has touched $389.5M on a worldwide basis, and has drawn within $18M of surpassing this summer's Pixar-mate <i>Cars 3</i> in domestic totals.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317573\" data-linked=\"Disney&#39;s &#39;Coco&#39; outpunches &#39;Justice League&#39; for third week\" data-tweet=\"$TWX $TWX $LGF.A - Disney&#39;s &#39;Coco&#39; outpunches &#39;Justice League&#39; for third week https://seekingalpha.com/news/3317573-disneys-coco-outpunches-justice-league-for-third-week?source=tweet\" data-url=\"https://seekingalpha.com/news/3317573-disneys-coco-outpunches-justice-league-for-third-week\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317572\" data-ts=\"1513023860\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLS\" target=\"_blank\">FLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317572-flowserve-downgraded-stifel-orders-look-weak\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Flowserve downgraded at Stifel as orders look weak</a></h4><ul>     <li>Flowserve (<a href='https://seekingalpha.com/symbol/FLS' title='Flowserve Corporation'>FLS</a> <font color='red'>-1.6%</font>) is <a href=\"https://www.streetinsider.com/Analyst+Comments/Stifel+Downgrades+Flowserve+Corp.+%28FLS%29+to+Hold/13586223.html\" target=\"_blank\">downgraded</a> to Hold from Buy with a $43 price target at Stifel, which cites no visible near term  catalysts and persistent operational issues in the company's industrial product division.</li><li>Stifel notes FLS's $893M in Q3 orders was the lowest in the current down cycle and management said it did not expect Q4 orders to perform any better; improving order rates will be the first sign that the cycle is turning, and with an expectation of flat to down orders in Q4, the firm does not see any near term catalysts for the stock.</li><li>Stifel believes considerable uncertainty remains around the timing of margin recovery in the industrial product division, which reduces confidence in its estimates.</li><li>FLS has dropped more than 3% since <a href=\"https://seekingalpha.com/news/3317316-johnson-controls-flowserve-cut-sell-goldman\" target=\"_blank\">last Friday</a>, when Goldman Sachs downgraded shares to Sell.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317572\" data-linked=\"Flowserve downgraded at Stifel as orders look weak\" data-tweet=\"$FLS - Flowserve downgraded at Stifel as orders look weak https://seekingalpha.com/news/3317572-flowserve-downgraded-stifel-orders-look-weak?source=tweet\" data-url=\"https://seekingalpha.com/news/3317572-flowserve-downgraded-stifel-orders-look-weak\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317570\" data-ts=\"1513023562\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317570-astrazenecas-acalabrutinib-shows-treatment-effect-in-cll-studies-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AstraZeneca&#39;s acalabrutinib shows treatment effect in CLL studies; shares up 1%</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17022764-astrazeneca-s-calquence-acalabrutinib-shows-potential-chronic-lymphocytic-leukemia-trials\" target=\"_blank\">Results</a> from two Phase 1/2 clinical trials showed AstraZeneca's (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a> <font color='green'>+1.2%</font>) CALQUENCE (acalabrutinib) delivered a significant treatment benefit in patients with chronic lymphocytic leukemia &#40;CLL&#41;. The data were presented at ASH in Atlanta.</li><li>Phase 1b/2 ACE-CL-003 demonstrated that the combination of acalabrutinib and Roche's Gazyva (obinutuzumab) produced a 95% overall response rate &#40;ORR&#41; (n=18/19) in treatment-naive CLL patients and 92% (n=24/26) in treatment-experienced patients. The complete response rates were 16% and 8%, respectively.</li><li>On the safety front, there was a long list of adverse events but the grades were not specified. There was one case of serious intermittent atrial fibrillation in a patient with that history, but it was determined to be unrelated to treatment.</li><li>Phase 1/2 ACE-CL-001 assessing monotherapy acalabrutinib showed an ORR of 87% with a 4% complete response rate. 18-month progression-free survival was 90%.</li><li>Acalabrutinib is an orally available second generation inhibitor of an enzyme called&nbsp;<a href=\"https://en.wikipedia.org/wiki/Bruton%27s_tyrosine_kinase\" target=\"_blank\">Bruton's tyrosine kinase</a>&nbsp;&#40;BTK&#41; that is in development for the treatment of a range of cancers. AstraZeneca secured the rights via its acquisition of a majority stake in Dutch biotch Acerta Pharma in 2016.</li><li>Previously: <a href=\"https://seekingalpha.com/news/2989456-astrazeneca-buys-55-percent-acerta-pharma-4b\" target=\"_blank\">AstraZeneca buys 55% of Acerta Pharma for $4B</a> (Dec. 17, 2015)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317570\" data-linked=\"AstraZeneca&#39;s acalabrutinib shows treatment effect in CLL studies; shares up 1%\" data-tweet=\"$AZN - AstraZeneca&#39;s acalabrutinib shows treatment effect in CLL studies; shares up 1% https://seekingalpha.com/news/3317570-astrazenecas-acalabrutinib-shows-treatment-effect-in-cll-studies-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3317570-astrazenecas-acalabrutinib-shows-treatment-effect-in-cll-studies-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317569\" data-ts=\"1513023340\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VMW\" target=\"_blank\">VMW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317569-t-rowe-price-discloses-vmware-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">T. Rowe Price discloses VMware stake</a></h4><ul><li>T. Rowe Price <a href=\"https://seekingalpha.com/filing/3794658\" target=\"_blank\">discloses</a> an 11.3% stake in VMware (NYSE:<a href='https://seekingalpha.com/symbol/VMW' title='VMware, Inc.'>VMW</a>).</li><li>VMware shares are<font color='green'>&nbsp;up 1.2%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3315768-analysts-make-vmware-adjustments-earnings\" target=\"_blank\">Analysts make VMware adjustments after earnings</a> (Dec. 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317569\" data-linked=\"T. Rowe Price discloses VMware stake\" data-tweet=\"$VMW - T. Rowe Price discloses VMware stake https://seekingalpha.com/news/3317569-t-rowe-price-discloses-vmware-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3317569-t-rowe-price-discloses-vmware-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317564\" data-ts=\"1513022423\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYMC\" target=\"_blank\">SYMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317564-symantec-security-products-come-to-oracle-cloud\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Symantec security products come to Oracle Cloud</a></h4><ul><li>Symantec (NASDAQ:<a href='https://seekingalpha.com/symbol/SYMC' title='Symantec Corporation'>SYMC</a>) <a href=\"https://seekingalpha.com/pr/17023222-symantec-cloud-security-solutions-now-available-oracle-cloud-marketplace\" target=\"_blank\">announces</a> that major components of its Integrated Cyber Defense Platform are now available through the Oracle (NYSE:<a href='https://seekingalpha.com/symbol/ORCL' title='Oracle Corporation'>ORCL</a>) Cloud Marketplace.</li><li>Available cloud security solutions include Control Compliance Suite, Data Center Security, Data Loss Prevention, and Endpoint Protection.</li><li>Symantec shares are<font color='green'> up 4.8%</font>.</li><li>Oracle shares are&nbsp;<font color='green'>up 1.5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317564\" data-linked=\"Symantec security products come to Oracle Cloud\" data-tweet=\"$SYMC $NLOK $ORCL - Symantec security products come to Oracle Cloud https://seekingalpha.com/news/3317564-symantec-security-products-come-to-oracle-cloud?source=tweet\" data-url=\"https://seekingalpha.com/news/3317564-symantec-security-products-come-to-oracle-cloud\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317563\" data-ts=\"1513022335\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317563-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='green'>+32%</font>. <a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/UTSI' title='UTStarcom, Inc.'>UTSI</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/MARK' title='Remark Holdings, Inc.'>MARK</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corp.'>TCCO</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/QUMU' title='Qumu Corporation'>QUMU</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/QBAK' title='Qualstar Corporation'>QBAK</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/RESN' title='Resonant'>RESN</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317563\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$NETE $XNET $UTSI - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3317563-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3317563-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317562\" data-ts=\"1513022018\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWTR\" target=\"_blank\">TWTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317562-twitter-engagement-up-long-tweets-new-bloomberg-streaming-news-coming\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twitter engagement up with long tweets; new Bloomberg streaming news coming</a></h4><ul>   <li>Twitter (<a href=\"http://seekingalpha.com/symbol/TWTR\" target=\"_blank\">TWTR</a> <font color='green'>+4.7%</font>) is <a href=\"https://www.buzzfeed.com/alexkantrowitz/early-data-shows-longer-tweets-are-a-hit-with-twitters-users?utm_term=.mjQXo7m3N#.ngg5eBdAy\" target=\"_blank\">seeing deeper engagement</a> since its much-publicized move to longer tweets, a BuzzFeed look at data shows.</li>    <li>Retweets and likes of tweets are happening at about double the rate from before tweets were extended to 280 characters from 140, BuzzFeed says based on data from SocialFlow.</li>    <li>During an experimental pilot period, people who had the additional room got more followers and spent more time on Twitter, the company says.</li>    <li>Meanwhile in Twitter-as-a-live-platform news, Bloomberg is <a href=\"https://twitter.com/tictoc/status/940236915734994945\" target=\"_blank\">launching \"TicToc,\"</a> a 24-hour news network that will be streaming live on the service. It's set to launch next Monday.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317562\" data-linked=\"Twitter engagement up with long tweets; new Bloomberg streaming news coming\" data-tweet=\"$TWTR - Twitter engagement up with long tweets; new Bloomberg streaming news coming https://seekingalpha.com/news/3317562-twitter-engagement-up-long-tweets-new-bloomberg-streaming-news-coming?source=tweet\" data-url=\"https://seekingalpha.com/news/3317562-twitter-engagement-up-long-tweets-new-bloomberg-streaming-news-coming\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317561\" data-ts=\"1513021941\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SOI\" target=\"_blank\">SOI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317561-solaris-oilfieldplus-6-on-deal-for-railtronix-assets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Solaris Oilfield +6% on deal for Railtronix assets</a></h4><ul>     <li>Solaris Oilfield Infrastructure (<a href='https://seekingalpha.com/symbol/SOI' title='Solaris Oilfield Infrastructure'>SOI</a> <font color='green'>+6.2%</font>) shoots higher after <a href=\"https://seekingalpha.com/pr/17022911-solaris-announces-acquisition-railtronix-expanding-supply-chain-digitalization-capabilities\" target=\"_blank\">agreeing to acquire</a> Railtronix, a Houston-based provider of real-time inventory management solutions for proppant mining, rail shipping and transloading operations; financial terms are not disclosed.</li>     <li>Railtronix&rsquo;s founder and CEO Alfonso Olvera will join SOI as Senior VP of Technology.</li>     <li>SOI expects the transaction to be accretive to earnings in 2018.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317561\" data-linked=\"Solaris Oilfield +6% on deal for Railtronix assets\" data-tweet=\"$SOI - Solaris Oilfield +6% on deal for Railtronix assets https://seekingalpha.com/news/3317561-solaris-oilfieldplus-6-on-deal-for-railtronix-assets?source=tweet\" data-url=\"https://seekingalpha.com/news/3317561-solaris-oilfieldplus-6-on-deal-for-railtronix-assets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317560\" data-ts=\"1513021573\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNSS\" target=\"_blank\">SNSS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317560-sunesis-up-28-after-ash-conference-wells-fargo-analyst-reconsiders\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sunesis up 28% after ASH conference; Wells Fargo analyst reconsiders</a></h4><ul><li>via Bloomberg's Gregory Calderone</li><li>Analyst Jim Birchenough less than one week ago, pulled his Outperform rating on Sunesis (NASDAQ:<a href='https://seekingalpha.com/symbol/SNSS' title='Sunesis Pharmaceuticals, Inc.'>SNSS</a>), figuring the exit of the CEO just head of the upcoming ASH conference wasn't a good sign.</li><li>He's changed his tune post-meeting though, upgrading to Outperform based on updated data on vecabrutinib and conference feedback telling him the drug could be the go-to option in a $3B market for BTK inhibitors.</li><li>He's now pricing in a 20% chance of success for vecabrutinib, up from 10% previously.</li><li><a href=\"http://ir.sunesis.com/static-files/52517a5d-4b17-4842-9de7-77e84bfbdda4\" target=\"_blank\">Presentation slides here</a></li><li>The stock's&nbsp;<font color='green'>higher by 28%</font>&nbsp;today.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317560\" data-linked=\"Sunesis up 28% after ASH conference; Wells Fargo analyst reconsiders\" data-tweet=\"$SNSS - Sunesis up 28% after ASH conference; Wells Fargo analyst reconsiders https://seekingalpha.com/news/3317560-sunesis-up-28-after-ash-conference-wells-fargo-analyst-reconsiders?source=tweet\" data-url=\"https://seekingalpha.com/news/3317560-sunesis-up-28-after-ash-conference-wells-fargo-analyst-reconsiders\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317558\" data-ts=\"1513020781\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYTK\" target=\"_blank\">CYTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317558-cytokinetics-discusses-tirasemtiv-results-down-2_5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cytokinetics further discusses tirasemtiv results; down 2.5%</a></h4><ul><li>\"Although we are profoundly disappointed with these results, we believe that data from VITALITY-ALS provide validation for the mechanism of action of fast skeletal muscle troponin activation,\" says Cytokinetics (<a href='https://seekingalpha.com/symbol/CYTK' title='Cytokinetics, Incorporated'>CYTK</a> <font color='red'>-2.5%</font>) CEO Robert Blum, presenting at an ALS symposium.</li><li>\"The increased numbers of non-serious adverse effects and drop-outs in patients who received tirasemtiv confound our ability to evaluate efficacy and safety in the primary analyses of VITALITY-ALS.\"</li><li><a href=\"http://ir.cytokinetics.com/static-files/db7cb410-8457-4cb8-b65e-cb8f6c44c593\" target=\"_blank\">Corporate presentation</a></li><li>Source: <a href=\"https://seekingalpha.com/pr/17022584-cytokinetics-announces-presentation-results-vitality-als-28th-international-symposium-als-mnd\" target=\"_blank\">Press Release</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3315371-cytokinetics-next-gen-muscle-troponin-activator-shows-positive-action-early-stage-studies\" target=\"_blank\">Cytokinetics' next-gen muscle troponin activator shows positive action in early-stage studies</a> (Nov. 30)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3313773-cytokinetics-stops-developing-tirasemtiv-failed-late-stage-als-study-trading-halted\" target=\"_blank\">Cytokinetics stops developing tirasemtiv after failed late-stage ALS study; trading halted</a> (Nov. 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317558\" data-linked=\"Cytokinetics further discusses tirasemtiv results; down 2.5%\" data-tweet=\"$CYTK - Cytokinetics further discusses tirasemtiv results; down 2.5% https://seekingalpha.com/news/3317558-cytokinetics-discusses-tirasemtiv-results-down-2_5?source=tweet\" data-url=\"https://seekingalpha.com/news/3317558-cytokinetics-discusses-tirasemtiv-results-down-2_5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317555\" data-ts=\"1513020203\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HCA\" target=\"_blank\">HCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317555-hospital-sector-need-mergers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hospital sector could need more than mergers</a></h4><ul><li>The consolidation wave continues, with <a href=\"https://seekingalpha.com/news/3317381-hospital-giants-talks-merge\" target=\"_blank\">the <em>WSJ </em>last night reporting</a> merger talks between two major nonprofit hospital chains that would create an operator larger than current sector gorilla HCA Healthcare (NYSE:<a href='https://seekingalpha.com/symbol/HCA' title='HCA Holdings, Inc.'>HCA</a>).</li><li>Cost cuts are nice, but revenue pressures are growing, <a href=\"https://www.wsj.com/articles/despite-mergers-hospitals-are-in-serious-condition-1513017673\" target=\"_blank\">writes Charley Grant in the <em>WSJ</em></a>. The CVS/Aetna deal is likely to lead to more treatment taking place inside CVS's retail locations. Meanwhile UnitedHealth is building out its physician-care business with the purchase of DaVita Medical Group.</li><li>Then there's policy, and whatever might come out of D.C. isn't looking too favorable for hospitals at the moment.</li><li>Tenet Healthcare (<a href='https://seekingalpha.com/symbol/THC' title='Tenet Healthcare Corporation'>THC</a> <font color='green'>+3.5%</font>) and Community Health Systems (<a href='https://seekingalpha.com/symbol/CYH' title='Community Health Systems, Inc.'>CYH</a> <font color='green'>+1.5%</font>) are ahead today, but whether they can pull out of major slumps (<font color='red'>down 50% or more&nbsp;</font>over the last two years) is another question.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317555\" data-linked=\"Hospital sector could need more than mergers\" data-tweet=\"$HCA $HCA $THC - Hospital sector could need more than mergers https://seekingalpha.com/news/3317555-hospital-sector-need-mergers?source=tweet\" data-url=\"https://seekingalpha.com/news/3317555-hospital-sector-need-mergers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317553\" data-ts=\"1513019903\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317553-amazon-cuts-back-on-hiring-seattle-headquarters\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amazon cuts back on hiring at Seattle headquarters</a></h4><ul><li>Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) has cut back on hiring at its Seattle headquarters as the company searches for a location for its second headquarters, according to <a href=\"https://www.seattletimes.com/business/amazon/amazons-seattle-hiring-frenzy-slows-sharply-whats-going-on/\" target=\"_blank\">The Seattle Times</a>.</li><li>The company had about 3.5K open positions in Seattle last week, down from over 9K in June.</li><li>Several employees told The Seattle Times that Amazon is freezing hiring for some positions, postponing others, and reorganizing staff and teams to cut back on costs while improving efficiency.</li><li>Amazon closed its application period in October for cities hoping to become the home of HQ2.</li><li>Amazon shares are&nbsp;<font color='green'>up 0.45%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3302975-amazon-receives-238-proposals-hq2\" target=\"_blank\">Amazon receives 238 proposals for HQ2</a> (Oct. 23)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317553\" data-linked=\"Amazon cuts back on hiring at Seattle headquarters\" data-tweet=\"$AMZN - Amazon cuts back on hiring at Seattle headquarters https://seekingalpha.com/news/3317553-amazon-cuts-back-on-hiring-seattle-headquarters?source=tweet\" data-url=\"https://seekingalpha.com/news/3317553-amazon-cuts-back-on-hiring-seattle-headquarters\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317551\" data-ts=\"1513019174\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MKC\" target=\"_blank\">MKC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317551-credit-suisse-dives-mccormicks-mustard-potential\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Credit Suisse dives into McCormick&#39;s mustard potential</a></h4><ul> <li>Credit Suisse trims estimates on McCormick &amp; Company (<a href='https://seekingalpha.com/symbol/MKC' title='McCormick & Company, Inc.'>MKC</a> <font color='red'>-1%</font>) due to concerns on sluggish near-term mustard retail sales.</li> <li>The CS mustard analysis: \"While mustard represents only 2% of McCormick&rsquo;s overall business, investors will put outsized emphasis on its performance because it represents about 1/3 of the high-priced RB Foods acquisition. We expect McCormick to improve the marketing plans of the French&rsquo;s brand now that it has absorbed RB into its North American Consumer Division.\"</li> <li>The firm keeps an Outperform rating on McCormick on its view that strategic goals of the French's acquisition will eventurally be met.</li> <li>McCormick ponied up $4.2B for French's Mustard earlier this year.</li><li>Source: Analyst note</li></ul><div class=\"tiny-share-widget\" data-id=\"3317551\" data-linked=\"Credit Suisse dives into McCormick&#39;s mustard potential\" data-tweet=\"$MKC - Credit Suisse dives into McCormick&#39;s mustard potential https://seekingalpha.com/news/3317551-credit-suisse-dives-mccormicks-mustard-potential?source=tweet\" data-url=\"https://seekingalpha.com/news/3317551-credit-suisse-dives-mccormicks-mustard-potential\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317550\" data-ts=\"1513018905\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317550-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a> <font color='green'>+213%</font>. <a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/CENX' title='Century Aluminum Company'>CENX</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/METC' title='Ramaco'>METC</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/MMLP' title='Martin Midstream Partners L.P.'>MMLP</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/HOS' title='Hornbeck Offshore Services, Inc.'>HOS</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/LLEX' title='Lilis Energy, Inc.'>LLEX</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SNMX' title='Senomyx, Inc.'>SNMX</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/CDXC' title='ChromaDex Inc.'>CDXC</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317550\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$YTEN $AMRS $CENX - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3317550-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3317550-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317548\" data-ts=\"1513018405\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNY\" target=\"_blank\">SNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317548-fda-approves-sanofis-rapid-acting-insulin-analog-admelog-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA approves Sanofi&#39;s rapid-acting insulin analog Admelog; shares up 1%</a></h4><ul><li>The FDA <a href=\"https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm588466.htm\" target=\"_blank\">grants full approval</a> for Sanofi's (<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a> <font color='green'>+1.1%</font>) Admelog (insulin lispro injection), a rapid-acting human insulin analog to improve glycemic control in adults and children with diabetes.</li><li>The agency tentatively approved the product in September under the abbreviated 505(b)(2) pathway which allows the inclusion of data generated by others. In this case, Sanofi used safety and efficacy data generated by Eli Lilly (<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a> <font color='green'>+0.2%</font>) to support Humalog (insulin lispro injection). Tentative approval means that the marketing application was complete enough for approval but patent issues needed to be resolved.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3293310-fda-tentatively-oks-sanofis-fast-acting-insulin-admelog-shares-1-percent-lilly-2-percent\" target=\"_blank\">FDA tentatively OKs Sanofi's fast-acting insulin Admelog; shares up 1%; Lilly down 2%</a> (Sept. 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317548\" data-linked=\"FDA approves Sanofi&#39;s rapid-acting insulin analog Admelog; shares up 1%\" data-tweet=\"$SNY $SNY $LLY - FDA approves Sanofi&#39;s rapid-acting insulin analog Admelog; shares up 1% https://seekingalpha.com/news/3317548-fda-approves-sanofis-rapid-acting-insulin-analog-admelog-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3317548-fda-approves-sanofis-rapid-acting-insulin-analog-admelog-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317546\" data-ts=\"1513017342\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HTZ\" target=\"_blank\">HTZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317546-car-rental-stocks-track-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Car rental stocks track higher</a></h4><ul> <li>Investors are lapping up Hertz Global (<a href='https://seekingalpha.com/symbol/HTZ' title='Hertz Global Holdings, Inc.'>HTZ</a> <font color='green'>+6.8%</font>) and Avis Budget Group (<a href='https://seekingalpha.com/symbol/CAR' title='Avis Budget Group, Inc.'>CAR</a> <font color='green'>+2.6%</font>) again.</li> <li>In the case of Avis, SRS Investment Management boosted its active stake to almost 15% from 10%, while the buying in Hertz continues a gentle four-week uptrend.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3317546\" data-linked=\"Car rental stocks track higher\" data-tweet=\"$HTZ $HTZ $CAR - Car rental stocks track higher https://seekingalpha.com/news/3317546-car-rental-stocks-track-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3317546-car-rental-stocks-track-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317545\" data-ts=\"1513017341\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AFMD\" target=\"_blank\">AFMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317545-affimeds-lead-candidate-shows-treatment-benefit-in-early-stage-study-investors-unimpressed\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Affimed&#39;s lead candidate shows treatment benefit in early-stage study; investors unimpressed, shares down 27%</a></h4><ul><li>Thinly traded nano cap Affimed N.V. (<a href='https://seekingalpha.com/symbol/AFMD' title='Affimed Therapeutics'>AFMD</a> <font color='red'>-26.9%</font>) slumps on more than a 4x surge in volume on the heels of its <a href=\"https://seekingalpha.com/pr/17022834-affimed-presents-data-phase-1b-combination-study-afm13-pembrolizumab-ash\" target=\"_blank\">announcement </a>of interim results from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT02665650?term=NCT02665650&amp;rank=1\" target=\"_blank\">Phase 1b clinical trial </a>assessing lead candidate AFM13 combined with Merck's KEYTRUDA (pembrolizumab) in patients with relapsed/refractory Hodgkin lymphoma &#40;HL&#41;. The data were presented at ASH in Atlanta.</li><li>Patients receiving the combination experienced an 83% (n=5/6) overall response rate &#40;ORR&#41;, above the historical ORR of 58 - 63% for KEYTRUDA alone.</li><li>On the safety front, one dose-limited toxicity was observed in cohort 3 (the highest dose 7.0 mg/kg) which was an infusion reaction leading to discontinuation. Four Grade 3 (serious) adverse events were reported, three possibly related to AFM13 and KEYTRUDA: nausea, vomiting and the infusion-related reaction.</li><li>Investors appear disappointed with the slow pace of the 33-subject study. According to ClinicalTrials.gov, it started in May 2016 so it has taken a year and a half to generate data on six patients who were assessed for responses every 12 weeks.</li><li>AFM13 is a bispecific antibody that binds to a protein expressed in a range of T-cell and B-cell lymphomas called CD30 and to a protein expressed on the immune system's natural killer cells called CD16A, both of which play key roles in the activation of the immune system to detect and kill cancer cells.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317545\" data-linked=\"Affimed&#39;s lead candidate shows treatment benefit in early-stage study; investors unimpressed, shares down 27%\" data-tweet=\"$AFMD - Affimed&#39;s lead candidate shows treatment benefit in early-stage study; investors unimpressed, shares down 27% https://seekingalpha.com/news/3317545-affimeds-lead-candidate-shows-treatment-benefit-in-early-stage-study-investors-unimpressed?source=tweet\" data-url=\"https://seekingalpha.com/news/3317545-affimeds-lead-candidate-shows-treatment-benefit-in-early-stage-study-investors-unimpressed\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317542\" data-ts=\"1513015291\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRK\" target=\"_blank\">MRK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317542-fda-accepts-mercks-marketing-application-for-keytruda-for-type-of-lymphoma-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Merck&#39;s marketing application for Keytruda for type of lymphoma; shares up 2%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17022879-fda-accepts-supplemental-biologics-license-application-sbla-assigns-priority-review-merck-s\" target=\"_blank\">accepts for review </a>Merck's (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a> <font color='green'>+1.5%</font>) marketing application seeking approval for KEYTRUDA (pembrolizumab) to treat adult and pediatric patients with refractory primary mediastinal B-cell lymphoma &#40;PMBCL&#41; who have relapsed after at least two prior lines of therapy. The agency's action date under Priority Review status is April 3, 2018.</li><li>The data supporting the filing was generated in the KEYNOTE-170 study which showed a 41% response rate to treatment, including a 24% complete response rate.</li><li>PMBCL is a diffuse large B-cell lymphoma that originates in the thymus gland.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317542\" data-linked=\"FDA accepts Merck&#39;s marketing application for Keytruda for type of lymphoma; shares up 2%\" data-tweet=\"$MRK - FDA accepts Merck&#39;s marketing application for Keytruda for type of lymphoma; shares up 2% https://seekingalpha.com/news/3317542-fda-accepts-mercks-marketing-application-for-keytruda-for-type-of-lymphoma-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3317542-fda-accepts-mercks-marketing-application-for-keytruda-for-type-of-lymphoma-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317536\" data-ts=\"1513014522\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATNX\" target=\"_blank\">ATNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317536-athenex-out-licenses-lead-candidate-kxminus-01-for-up-to-275m-investors-unmoved-shares-down\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Athenex out-licenses lead candidate KX-01 for up to $275M; investors unmoved, shares down 13%</a></h4><ul><li>Thinly traded Athenex (<a href='https://seekingalpha.com/symbol/ATNX' title='Athenex, Inc.'>ATNX</a> <font color='red'>-13.2%</font>) slumps on a 7x surge in volume, albeit on turnover of only 860K shares, in apparent response to its <a href=\"https://seekingalpha.com/pr/17023516-almirall-athenex-announce-strategic-partnership-treatment-actinic-keratosis\" target=\"_blank\">license deal</a> with Almirall, S.A. for lead candidate KX-01 (also referred to a KX2-391). The companies will partner on the develop and commercialization of the topical med for the treatment of actinic keratosis and other skin conditions.</li><li>Under the terms of the agreement, Almirall will have exclusive rights in the U.S. and Europe, including Russia. Athenex will be responsible for all preclinical and clinical studies leading up to U.S. approval. Almiral will support development in Europe and will have commercialization rights in both the EU and U.S.</li><li>Athenex will receive $55M upfront, up to $65M in launch and additional indications milestones, up to $155M in sales milestones and tiered royalties starting at 15%.</li><li><a href=\"https://www.athenex.com/oncology-innovation/src-kinase-inhibitors/\" target=\"_blank\">KX-01</a> inhibits a proto-oncogene called <a href=\"https://en.wikipedia.org/wiki/Proto-oncogene_tyrosine-protein_kinase_Src\" target=\"_blank\">kinase Src</a>, of which elevated levels are associated with cancer progression.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317536\" data-linked=\"Athenex out-licenses lead candidate KX-01 for up to $275M; investors unmoved, shares down 13%\" data-tweet=\"$ATNX - Athenex out-licenses lead candidate KX-01 for up to $275M; investors unmoved, shares down 13% https://seekingalpha.com/news/3317536-athenex-out-licenses-lead-candidate-kxminus-01-for-up-to-275m-investors-unmoved-shares-down?source=tweet\" data-url=\"https://seekingalpha.com/news/3317536-athenex-out-licenses-lead-candidate-kxminus-01-for-up-to-275m-investors-unmoved-shares-down\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317538\" data-ts=\"1513014455\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317538-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a> <font color='green'>+215%</font>. <a href='https://seekingalpha.com/symbol/DAVE' title='Famous Dave&#39;s of America, Inc.'>DAVE</a> <font color='green'>+32%</font>. <a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='green'>+32%</font>. <a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/BPMC' title='Blueprint Medicines'>BPMC</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/CLSD' title='Clearside Biomedical'>CLSD</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a> <font color='green'>+19%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PZRX' title='PhaseRx'>PZRX</a> <font color='red'>-47%</font>. <a href='https://seekingalpha.com/symbol/GLBR' title='Global Brokerage, Inc.'>OTCPK:GLBR</a> <font color='red'>-46%</font>. <a href='https://seekingalpha.com/symbol/ONCE' title='Spark Therapeutics'>ONCE</a> <font color='red'>-34%</font>. <a href='https://seekingalpha.com/symbol/VTGN' title='VistaGen Therapeutics, Inc.'>VTGN</a> <font color='red'>-33%</font>. <a href='https://seekingalpha.com/symbol/SYRS' title='Syros Pharmaceuticals'>SYRS</a> <font color='red'>-31%</font>. <a href='https://seekingalpha.com/symbol/AFMD' title='Affimed Therapeutics'>AFMD</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/LMFA' title='LM Funding America, Inc.'>LMFA</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/BEBE' title='bebe stores, inc.'>OTC:BEBE</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/TRIL' title='Trillium Therapeutics Inc.'>TRIL</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a>&nbsp;<font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317538\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$YTEN $BBQ $NETE - Midday Gainers / Losers https://seekingalpha.com/news/3317538-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3317538-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317535\" data-ts=\"1513013567\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIEGY\" target=\"_blank\">SIEGY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317535-siemens-returns-to-libya-700m-in-power-generation-deals\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Siemens returns to Libya with \u20ac700M in power generation deals</a></h4><ul>     <li>Siemens (<a href='https://seekingalpha.com/symbol/SIEGY' title='Siemens AG ADR'>OTCPK:SIEGY</a> <font color='green'>+2%</font>) says it has signed <a href=\"https://www.nytimes.com/reuters/2017/12/11/business/11reuters-siemens-libya.html\" target=\"_blank\">power generation contracts with Libya</a> worth ~&euro;700M, marking a return to active business in the country following the unrest that broke out after the 2011 uprising.</li>     <li>Siemens will build and service two gas-power plants in Misrata and west Tripoli, adding ~1.3 GW to Libya's electricity generation capacity.</li>     <li>The company also is building out power generation capacity in neighboring Egypt, where it won an &euro;8B contract, the biggest in its history, in 2015.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317535\" data-linked=\"Siemens returns to Libya with \u20ac700M in power generation deals\" data-tweet=\"$SIEGY - Siemens returns to Libya with \u20ac700M in power generation deals https://seekingalpha.com/news/3317535-siemens-returns-to-libya-700m-in-power-generation-deals?source=tweet\" data-url=\"https://seekingalpha.com/news/3317535-siemens-returns-to-libya-700m-in-power-generation-deals\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317534\" data-ts=\"1513012884\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOX\" target=\"_blank\">FOX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317534-wsj-fox-disney-deal-mean-scaled-back-film-slate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WSJ: A Fox-Disney deal would mean scaled-back film slate</a></h4><ul>   <li>A megadeal to bring the TV and film assets of Twenty-First Century Fox (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color='red'>-0.2%</font>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='green'>+0.3%</font>) under the auspices of Walt Disney (<a href=\"http://seekingalpha.com/symbol/DIS\" target=\"_blank\">DIS</a> <font color='green'>+1.7%</font>) would not just reduce the Big Six Hollywood studios to five, but would mean a <a href=\"https://www.wsj.com/articles/disney-deal-for-fox-would-end-era-of-the-big-six-studios-1512907201\" target=\"_blank\">significant scaling back of Fox's slate</a> as well, <i>The Wall Street Journal</i> reports.</li>    <li>The reduced ambitions would be folded into Disney's existing film operations rather than kept separate or expanded, according to the report.</li>    <li>Fox could become another production label akin to Pixar or Marvel, which would result in job cuts as theatrical and home video distribution are trimmed.</li>    <li>It would also mean output from Fox, known for releasing far more films than Disney, would fall in line with Disney output: fewer films, focused on big-budget releases based on existing properties.</li>    <li>While the era of the \"Big Six\" would come to an end, Fox's TV studio would be kept busy building content for the upcoming Disney streaming services as well as for other outlets.</li>    <li>In other news tied to a potential deal, United First Partners says in a weekend note that a purchase of the rest of Sky (<a href=\"http://seekingalpha.com/symbol/SKYAY\" target=\"_blank\">SKYAY</a> <font color='green'>+0.7%</font>) by either Disney or Comcast (<a href=\"http://seekingalpha.com/symbol/CMCSA\" target=\"_blank\">CMCSA</a> <font color='green'>+0.9%</font>) would be more palatable to UK regulators than Fox's current proposal to buy out the rest.</li>    <li>Those two don't have Fox's \"baggage,\" UFP says, so a consummated deal for Fox assets would mean gains for Sky stock.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317534\" data-linked=\"WSJ: A Fox-Disney deal would mean scaled-back film slate\" data-tweet=\"$FOX $FOX $FOXA - WSJ: A Fox-Disney deal would mean scaled-back film slate https://seekingalpha.com/news/3317534-wsj-fox-disney-deal-mean-scaled-back-film-slate?source=tweet\" data-url=\"https://seekingalpha.com/news/3317534-wsj-fox-disney-deal-mean-scaled-back-film-slate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317533\" data-ts=\"1513012857\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BH-OLD\" target=\"_blank\">BH-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317533-restaurant-stocks-perky-led-moonshot-for-famous-daves\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Restaurant stocks perky, led by moonshot for Famous Dave&#39;s</a></h4><ul> <li>There's some buying action in the restaurant sector as M&amp;A potential and strong consumer spending continue to boost sentiment.</li> <li>Notable gainers include Biglari Holdings (<a href='https://seekingalpha.com/symbol/BH-OLD' title='Biglari Holdings Inc.'>BH-OLD</a> <font color='green'>+5.5%</font>), Zoe's Kitchen (<a href='https://seekingalpha.com/symbol/ZOES' title='Zoe&#39;s Kitchen'>ZOES</a> <font color='green'>+2.3%</font>), Sonic (<a href='https://seekingalpha.com/symbol/SONC' title='Sonic Corp.'>SONC</a> <font color='green'>+2.7%</font>), Fiesta Restaurant Group (<a href='https://seekingalpha.com/symbol/FRGI' title='Fiesta Restaurant Group, Inc.'>FRGI</a> <font color='green'>+2%</font>) and Brinker International (<a href='https://seekingalpha.com/symbol/EAT' title='Brinker International, Inc.'>EAT</a> <font color='green'>+2.5%</font>).</li> <li>None of those rallies can hold a candle to the 32% pop in Famous Dave's of America (NASDAQ:<a href='https://seekingalpha.com/symbol/DAVE' title='Famous Dave&#39;s of America, Inc.'>DAVE</a>) on a huge volume spike. Shares of the barbecue chain traded as high as $9.65 before settling back to $7.25 after a trading halt.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317533\" data-linked=\"Restaurant stocks perky, led by moonshot for Famous Dave&#39;s\" data-tweet=\"$BH-OLD $BH-OLD $ZOES - Restaurant stocks perky, led by moonshot for Famous Dave&#39;s https://seekingalpha.com/news/3317533-restaurant-stocks-perky-led-moonshot-for-famous-daves?source=tweet\" data-url=\"https://seekingalpha.com/news/3317533-restaurant-stocks-perky-led-moonshot-for-famous-daves\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317531\" data-ts=\"1513012669\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JUNO\" target=\"_blank\">JUNO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317531-junos-jcar017-shows-74-response-rate-in-early-stage-nhl-study-investors-unmoved-shares-down\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Juno&#39;s JCAR017 shows 74% response rate in early-stage NHL study; investors unmoved, shares down 11%</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17022903-juno-therapeutics-celgene-corporation-release-additional-data-transcend-trial-jcar017\" target=\"_blank\">New data</a> from the Phase 1 TRANSCEND study assessing Juno Therapeutics' (<a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a> <font color='red'>-10.9%</font>) CAR-T candidate JCAR017 in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma &#40;NHL&#41; showed a significant treatment benefit. The results were presented at ASH in Atlanta.</li><li>At dose level 2 (DL2)(100M cells), the overall response rate &#40;ORR&#41; at month 3 was 74% (n=14/19), including 13 (68%) complete responders. In the group of patients who reached six months of follow-up, half (n=7/14) were in complete remission.</li><li>On the safety front, one patient (n=1/67) in the core group experienced severe cytokine release syndrome &#40;CRS&#41; and 15% (n=10/67) experienced severe neurotoxicity &#40;NT&#41;. In the DL2 arm, there were no cases of CRS and two cases (n=2/29) of NT.</li><li>The company is developing JCAR017 with Celgene (<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a> <font color='green'>+2.2%</font>). A U.S. marketing application is on tap in H2 2018 with possible approval as early as year-end 2018.</li><li>Investors appear to be reacting to the neurotoxicity data in the context of what happened to JCAR015. The company terminated development of the former lead candidate due to an unacceptable rate of cerebral edema.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317531\" data-linked=\"Juno&#39;s JCAR017 shows 74% response rate in early-stage NHL study; investors unmoved, shares down 11%\" data-tweet=\"$JUNO $JUNO $CELG - Juno&#39;s JCAR017 shows 74% response rate in early-stage NHL study; investors unmoved, shares down 11% https://seekingalpha.com/news/3317531-junos-jcar017-shows-74-response-rate-in-early-stage-nhl-study-investors-unmoved-shares-down?source=tweet\" data-url=\"https://seekingalpha.com/news/3317531-junos-jcar017-shows-74-response-rate-in-early-stage-nhl-study-investors-unmoved-shares-down\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317529\" data-ts=\"1513011642\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317529-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CLXT' title='Calyxt, Inc.'>CLXT</a> <font color='green'>+11%</font>. XNY <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/FUV' title='Arcimoto, Inc.'>FUV</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/WKHS' title='Workhorse Group Inc.'>WKHS</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/SORL' title='SORL Auto Parts, Inc.'>SORL</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> LTEA <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/VNCE' title='Vince Holding Corp.'>VNCE</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/AVP' title='Avon Products, Inc.'>AVP</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317529\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$CLXT $DXF $FUV - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3317529-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3317529-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317518\" data-ts=\"1513008945\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317518-techcrunch-apple-will-announce-shazam-acquisition-today-paid-400m-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TechCrunch: Apple will announce Shazam acquisition today, paid about $400M (update)</a></h4><ul><li>TechCrunch says Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) will announce its Shazam acquisition today.</li><li>Apple reportedly paid around $400M for the music recognition service after months of discussions and competing interest from Snap and Spotify.</li><li>Shazam had a $1B valuation after its last round of financing.</li><li>Apple shares are&nbsp;<font color='green'>up 1.5%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317317-techcrunch-apple-will-acquire-shazam-app\" target=\"_blank\">TechCrunch: Apple will acquire Shazam app</a> (Dec. 8)</li><li>Update: Apple <a href=\"https://www.buzzfeed.com/daveyalba/yep-apple-is-buying-shazam-the-music-recognition-app?utm_term=.xmQGyxmBQ#.drovPJ6pg\" target=\"_blank\">confirms</a> the acquisition to Buzzfeed but doesn't disclose the price.</li><li>Apple calls Shazam and Apple Music \"a natural fit\" and says there are \"exciting plans in store.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3317518\" data-linked=\"TechCrunch: Apple will announce Shazam acquisition today, paid about $400M (update)\" data-tweet=\"$AAPL - TechCrunch: Apple will announce Shazam acquisition today, paid about $400M (update) https://seekingalpha.com/news/3317518-techcrunch-apple-will-announce-shazam-acquisition-today-paid-400m-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3317518-techcrunch-apple-will-announce-shazam-acquisition-today-paid-400m-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317486\" data-ts=\"1513008571\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317486-healthcare-top-5-gainers-losers-of-11-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:05 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/TYHT' title='Shineco, Inc.'>TYHT</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/CHFS' title='CHF Solutions, Inc.'>CHFS</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/BPMC' title='Blueprint Medicines'>BPMC</a> <font color='green'>+17%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PZRX' title='PhaseRx'>PZRX</a> <font color='red'>-47%</font>. <a href='https://seekingalpha.com/symbol/ONCE' title='Spark Therapeutics'>ONCE</a> <font color='red'>-40%</font>. <a href='https://seekingalpha.com/symbol/SYRS' title='Syros Pharmaceuticals'>SYRS</a> <font color='red'>-36%</font>. <a href='https://seekingalpha.com/symbol/VTGN' title='VistaGen Therapeutics, Inc.'>VTGN</a> <font color='red'>-33%</font>. <a href='https://seekingalpha.com/symbol/AFMD' title='Affimed Therapeutics'>AFMD</a> <font color='red'>-18%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317486\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:05 am\" data-tweet=\"$TYHT $CHFS $BLUE - Healthcare - Top 5 Gainers / Losers as of 11:05 am https://seekingalpha.com/news/3317486-healthcare-top-5-gainers-losers-of-11-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3317486-healthcare-top-5-gainers-losers-of-11-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317509\" data-ts=\"1513008264\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TYHT\" target=\"_blank\">TYHT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317509-shineco-inks-share-exchange-and-acquisition-agreement-chinese-nursery-operator-shares-up-24\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shineco inks share exchange and acquisition agreement with Chinese nursery operator; shares up 24%</a></h4><ul><li>Chinese herbal medicine maker Shineco (<a href='https://seekingalpha.com/symbol/TYHT' title='Shineco, Inc.'>TYHT</a> <font color='green'>+23.7%</font>) is up on 67% higher volume, albeit on turnover of only 188K shares, in response to its share exchange and acquisition <a href=\"https://seekingalpha.com/pr/17023325-shineco-inc-enters-definitive-share-exchange-acquisition-agreement-western-xinjiang-tiansheng\" target=\"_blank\">agreement </a>with strategic partner Western Xinjiang Tiansheng Agricultural Development Co., Ltd.</li><li>Under the terms of the agreement, joint venture company Xinjiang Shineco Taihe Agricultural Technology Ltd. will receive a 51% stake in Xinjiang Tiansheng in exchange for a 14% stake in Xinjiang Taihe plus three cash payments with an aggregate value of RMB23.8M (US$3.57M), contingent on certain milestones.</li><li>Shineco says the investment will further its expansion into the apocynum (Indian hemp) business.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317509\" data-linked=\"Shineco inks share exchange and acquisition agreement with Chinese nursery operator; shares up 24%\" data-tweet=\"$TYHT - Shineco inks share exchange and acquisition agreement with Chinese nursery operator; shares up 24% https://seekingalpha.com/news/3317509-shineco-inks-share-exchange-and-acquisition-agreement-chinese-nursery-operator-shares-up-24?source=tweet\" data-url=\"https://seekingalpha.com/news/3317509-shineco-inks-share-exchange-and-acquisition-agreement-chinese-nursery-operator-shares-up-24\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317513\" data-ts=\"1513008221\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMASY\" target=\"_blank\">IMASY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317513-inmarsat-tumbles-goldman-cuts-expectations-until-late-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Inmarsat tumbles as Goldman cuts expectations until late 2018</a></h4><ul>   <li>Inmarsat (<a href='https://seekingalpha.com/symbol/IMASY' title='Inmarsat Plc. ADR'>OTCPK:IMASY</a>) is <font color='red'>5.8% lower</font> in U.S. trading (and <font color='red'>down 8%</font> in London) amid a Goldman Sachs downgrade to Neutral on low optimism for an earnings turnaround.</li>    <li>The company's dividend has \"broadly been uncovered\" by free cash flow since 2011, Goldman notes, and Inmarsat is seeing higher costs in building out its in-flight connectivity business along with legacy declines. (h/t Bloomberg)</li>    <li>There's limited scope for positive momentum in earnings until late 2018, Goldman says.</li>    <li>The firm has cut its price target to 580 pence from 860 pence, implying 19% upside from yesterday's close.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317513\" data-linked=\"Inmarsat tumbles as Goldman cuts expectations until late 2018\" data-tweet=\"$IMASY $IMASF - Inmarsat tumbles as Goldman cuts expectations until late 2018 https://seekingalpha.com/news/3317513-inmarsat-tumbles-goldman-cuts-expectations-until-late-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3317513-inmarsat-tumbles-goldman-cuts-expectations-until-late-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317510\" data-ts=\"1513007691\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAM\" target=\"_blank\">BAM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317510-ggp-edges-higher-after-reportedly-rejecting-brookfield-proposal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GGP edges higher after reportedly rejecting Brookfield proposal</a></h4><ul><li>One doesn't have to have read \"Art of the Deal\" to know it often pays to begin with a lowball offer. That's been Brookfield's (NYSE:<a href='https://seekingalpha.com/symbol/BAM' title='Brookfield Asset Management Inc.'>BAM</a>) pattern, and <a href=\"https://seekingalpha.com/news/3317378-reuters-ggp-rejects-23-share-offer-brookfield-property-partners\" target=\"_blank\">reports last night</a> say GGP rejected Brookfield Property's (NYSE:<a href='https://seekingalpha.com/symbol/BPY' title='Brookfield Property Partners L.P.'>BPY</a>) $23 cash and stock offer for the 66% of GGP it doesn't already own.</li><li>Brookfield is reportedly mulling a new bid.</li><li>GGP is&nbsp;<font color='green'>up 0.6%&nbsp;</font>to $23.57, and BPY is&nbsp;<font color='red'>down 0.8%</font>.</li><li>Meanwhile, Evercore ISI's Steve Sakwa downgrades BPY to Inline from Outperform, figuring investors will stay on the sidelines until they get more certainty on a deal.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317510\" data-linked=\"GGP edges higher after reportedly rejecting Brookfield proposal\" data-tweet=\"$BAM $BAM $BPR - GGP edges higher after reportedly rejecting Brookfield proposal https://seekingalpha.com/news/3317510-ggp-edges-higher-after-reportedly-rejecting-brookfield-proposal?source=tweet\" data-url=\"https://seekingalpha.com/news/3317510-ggp-edges-higher-after-reportedly-rejecting-brookfield-proposal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317508\" data-ts=\"1513007418\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FBHS\" target=\"_blank\">FBHS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317508-fortune-brands-announces-new-250m-buyback-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fortune Brands announces new $250M buyback plan</a></h4><ul> <li>Fortune Brands Home &amp; Security (<a href='https://seekingalpha.com/symbol/FBHS' title='Fortune Brands Home & Security, Inc.'>FBHS</a> <font color='green'>+0.1%</font>) announces that its board authorized the       repurchase of up to $250M worth of shares over the next two years.</li><li>The company says it has approximately $300M existing from a       prior authorization that expires February 28, 2019 to bring the total       share repurchase authorization to approximately $550M.</li>     <li>\"In addition to organic growth, we use our strong cash flow and balance       sheet to drive incremental shareholder value by investing in Fortune       Brands&rsquo; businesses, pursuing accretive acquisitions, and returning cash       to shareholders,\" says Fortune Brands CEO&nbsp;Chris Klein.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317434-fortune-brands-home-and-security-declares-0_20-dividend\" target=\"_blank\">Fortune Brands Home &amp; Security declares $0.20 dividend</a> (Dec. 11)</li><li>Source: <a href=\"https://seekingalpha.com/pr/17023056-fortune-brands-increases-quarterly-dividend-announces-250-million-share-repurchase\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3317508\" data-linked=\"Fortune Brands announces new $250M buyback plan\" data-tweet=\"$FBHS - Fortune Brands announces new $250M buyback plan https://seekingalpha.com/news/3317508-fortune-brands-announces-new-250m-buyback-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3317508-fortune-brands-announces-new-250m-buyback-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317504\" data-ts=\"1513006540\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARCH\" target=\"_blank\">ARCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317504-arch-coalplus-2-after-500k-share-buyback-deal-no-2-shareholder\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arch Coal +2% after 500K-share buyback deal with no. 2 shareholder</a></h4><ul>     <li>Arch Coal (<a href='https://seekingalpha.com/symbol/ARCH' title='Arch Coal Inc'>ARCH</a> <font color='green'>+1.9%</font>) zooms to a YTD high after announcing a deal to <a href=\"https://seekingalpha.com/pr/17022873-arch-coal-inc-announces-stock-repurchase-agreement-monarch-alternative-capital\" target=\"_blank\">buy back 500K shares</a> from Morgan Alternative Capital, its second-largest shareholder, at $83.03/share.</li><li>Arch says the $41.5M repurchase is part of its existing $500M stock buyback program.</li><li>Monarch <a href=\"https://www.marketwatch.com/story/arch-coals-stock-rallies-to-record-after-500000-shares-buyback-deal-2017-12-11\" target=\"_blank\">owned 2.56M Arch shares</a>, or 10.5% of shares outstanding as of Sept. 30, which ranked second to Oppenheimer Funds' 13.6M shares outstanding.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317504\" data-linked=\"Arch Coal +2% after 500K-share buyback deal with no. 2 shareholder\" data-tweet=\"$ARCH - Arch Coal +2% after 500K-share buyback deal with no. 2 shareholder https://seekingalpha.com/news/3317504-arch-coalplus-2-after-500k-share-buyback-deal-no-2-shareholder?source=tweet\" data-url=\"https://seekingalpha.com/news/3317504-arch-coalplus-2-after-500k-share-buyback-deal-no-2-shareholder\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:35 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317499\" data-ts=\"1513006037\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XENT\" target=\"_blank\">XENT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317499-fda-oks-intersect-ents-sinuva-sinus-implant-shares-up-17\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Intersect ENT&#39;s Sinuva sinus implant; shares up 17%</a></h4><ul><li>Thinly traded Intersect ENT (<a href='https://seekingalpha.com/symbol/XENT' title='Intersect ENT'>XENT</a> <font color='green'>+16.8%</font>) is up on modestly volume, albeit on turnover of only 168K shares, in response to its <a href=\"https://seekingalpha.com/pr/17023012-intersect-ent-announces-fda-approval-sinuva-sinus-implant-new-office-treatment-option\" target=\"_blank\">announcement </a>that the FDA has approved the SINUVA (mometasone furoate) Sinus Implant for treating recurrent nasal polyps in patients who have had previous ethmoid sinus surgery.</li><li>SINUVA, a device that delivers an anti-inflammatory steroid directly to the site of polyps, can be placed by a physician in an office setting.</li><li>The FDA's action was January 7, 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317499\" data-linked=\"FDA OKs Intersect ENT&#39;s Sinuva sinus implant; shares up 17%\" data-tweet=\"$XENT - FDA OKs Intersect ENT&#39;s Sinuva sinus implant; shares up 17% https://seekingalpha.com/news/3317499-fda-oks-intersect-ents-sinuva-sinus-implant-shares-up-17?source=tweet\" data-url=\"https://seekingalpha.com/news/3317499-fda-oks-intersect-ents-sinuva-sinus-implant-shares-up-17\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317498\" data-ts=\"1513005447\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FSIC-OLD\" target=\"_blank\">FSIC-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317498-kkr-replaces-blackstone-external-manager-of-fs-investment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KKR replaces Blackstone as external manager of FS Investment</a></h4><ul><li>It's been a rough run for FS Investment (NYSE:<a href='https://seekingalpha.com/symbol/FSIC-OLD' title='FS Investment Corporation'>FSIC-OLD</a>),&nbsp;<font color='red'>down 24%</font>&nbsp;this year and with a <a href=\"https://seekingalpha.com/news/3310930-fs-investment-declares-0_19-dividend\" target=\"_blank\">recently cut</a> dividend.</li><li>Perhaps, <a href='https://seekingalpha.com/symbol/KKR' title='KKR'>KKR</a> can do a better job. <a href=\"https://seekingalpha.com/pr/17022988-b-fs-b-investments-announces-fund-manager-changes-credit-team-expansion\" target=\"_blank\">It's taking over as </a>sub-advisor of the $4.1B in assets at FSIC, replacing Blackstone's (NYSE:<a href='https://seekingalpha.com/symbol/BX' title='The Blackstone Group L.P.'>BX</a>) GSO Capital (which has been there since launch in 2009). The BDC generated $54.7M of management fees through the first nine months of this year.</li><li>KKR is <a href=\"https://seekingalpha.com/pr/17022969-b-fs-b-investments-kkr-partnering-form-premier-18-billion-middle-market-alternative-lending\" target=\"_blank\">also taking over </a>joint-management (with FS) at a number of other FS Investment (the parent of FSIC) BDC vehicles. Combined, it'll have a giant (for BDCs) $18B in AUM. Included is Corporate Capital Trust (NYSE:<a href='https://seekingalpha.com/symbol/CCT' title='Corporate Capital Trust, Inc.'>CCT</a>), which KKR already managed prior to these agreements.</li><li>FSIC is flat on the session, CCT is&nbsp;<font color='red'>down 3.3%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317498\" data-linked=\"KKR replaces Blackstone as external manager of FS Investment\" data-tweet=\"$FSIC-OLD $FSIC-OLD $KKR - KKR replaces Blackstone as external manager of FS Investment https://seekingalpha.com/news/3317498-kkr-replaces-blackstone-external-manager-of-fs-investment?source=tweet\" data-url=\"https://seekingalpha.com/news/3317498-kkr-replaces-blackstone-external-manager-of-fs-investment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317497\" data-ts=\"1513005412\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDC\" target=\"_blank\">WDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317497-nikkei-western-digital-board-meets-today-to-discuss-toshiba-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nikkei: Western Digital board meets by today to discuss Toshiba deal</a></h4><ul><li>        <a href=\"https://asia.nikkei.com/Business/Companies/Toshiba-and-Western-Digital-close-to-ending-dispute-over-memory-sale\" target=\"_blank\">Nikkei Asian Review</a> reports that Western Digital&rsquo;s (NYSE:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) board will meet by today to discuss dropping its legal case blocking the sale of Toshiba&rsquo;s (<a href='https://seekingalpha.com/symbol/TOSBF' title='Toshiba Corp.'>OTCPK:TOSBF</a>, <a href='https://seekingalpha.com/symbol/TOSYY' title='Toshiba Corp. ADR'>OTCPK:TOSYY</a>) chip unit.</li><li>               Toshiba directors met last week and agreed to drop its legal case against Western Digital if the other company did the same.&nbsp;</li><li>                  Toshiba would also allow Western Digital to participate in the Fab 6 plant.      </li><li>                  Western Digital shares are&nbsp;<font color='green'>up 0.14%</font>.&nbsp;&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3317413-reuters-activist-investor-wants-toshiba-back-chip-unit-sale\" target=\"_blank\">Reuters: Activist investor wants Toshiba to back out of chip unit sale</a> (Dec. 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317497\" data-linked=\"Nikkei: Western Digital board meets by today to discuss Toshiba deal\" data-tweet=\"$WDC $WDC $TOSBF - Nikkei: Western Digital board meets by today to discuss Toshiba deal https://seekingalpha.com/news/3317497-nikkei-western-digital-board-meets-today-to-discuss-toshiba-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3317497-nikkei-western-digital-board-meets-today-to-discuss-toshiba-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317496\" data-ts=\"1513005336\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMCSA\" target=\"_blank\">CMCSA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317496-centurylink-named-network-provider-of-pennsylvania-sharesplus-8_1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CenturyLink named network provider of Pennsylvania; shares +8.1%</a></h4><ul>   <li>CenturyLink (<a href=\"http://seekingalpha.com/symbol/CTL\" target=\"_blank\">CTL</a> <font color='green'>+8.1%</font>) has been selected as the <a href=\"https://seekingalpha.com/pr/17023002-centurylink-selected-network-provider-commonwealth-pennsylvania\" target=\"_blank\">network provider to Pennsylvania</a>, a deal that will have it supplying a full suite of products and services to the Commonwealth.</li>    <li>The company will collaborate with Comcast Business (<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a> <font color='green'>+0.6%</font>) on the five-year deal, which covers a range of deliverables: microwave and fixed satellite data access, Ethernet, private line, managed network services, virtual private networks, high speed cellular, bandwidth on demand and others.</li>    <li>The deal in particular looks to address last-mile solutions (fiber, coaxial and wireless) to the agencies, commissions, councils, bureaus, authorities and boards of Pennsylvania.</li>    <li>CenturyLink operates more than 7,700 route-miles of fiber in the state, with more than 2,200 on-net buildings.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317496\" data-linked=\"CenturyLink named network provider of Pennsylvania; shares +8.1%\" data-tweet=\"$CMCSA $CMCSA $CTL - CenturyLink named network provider of Pennsylvania; shares +8.1% https://seekingalpha.com/news/3317496-centurylink-named-network-provider-of-pennsylvania-sharesplus-8_1?source=tweet\" data-url=\"https://seekingalpha.com/news/3317496-centurylink-named-network-provider-of-pennsylvania-sharesplus-8_1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317488\" data-ts=\"1513004401\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PZRX\" target=\"_blank\">PZRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317488-phaserx-declares-chapter-11-shares-down-48\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PhaseRx declares Chapter 11; shares down 48%</a></h4><ul><li>PhaseRx (<a href='https://seekingalpha.com/symbol/PZRX' title='PhaseRx'>PZRX</a> <font color='red'>-47.5%</font>) slumps on increased volume in response to its <a href=\"https://seekingalpha.com/pr/17022958-phaserx-commences-voluntary-chapter-11-bankruptcy-protection-proceeding\" target=\"_blank\">announcement </a>that it intends to file for Chapter 11 bankruptcy protection. It will continue its operations while it explores strategic alternatives. Cowen and Company is advising.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317488\" data-linked=\"PhaseRx declares Chapter 11; shares down 48%\" data-tweet=\"$PZRX - PhaseRx declares Chapter 11; shares down 48% https://seekingalpha.com/news/3317488-phaserx-declares-chapter-11-shares-down-48?source=tweet\" data-url=\"https://seekingalpha.com/news/3317488-phaserx-declares-chapter-11-shares-down-48\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317484\" data-ts=\"1513003992\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBIO\" target=\"_blank\">CBIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317484-catalyst-bio-up-13-on-positive-phase-1-2-data-on-hemophilia-b-candidate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Catalyst Bio up 13% on positive Phase 1/2 data on hemophilia B candidate</a></h4><ul><li>Thinly traded nano cap Catalyst Biosciences (<a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a> <font color='green'>+12.7%</font>) perks up on the heels of the <a href=\"https://seekingalpha.com/pr/17023097-catalyst-biosciences-announces-interim-phase-1-2-cb-2679d-isu304-results-american-society\" target=\"_blank\">presentation </a>of Phase 1/2 data on hemophilia B candidate CB 2679d at ASH in Atlanta.</li><li>Results showed that subcutaneous delivery of a single dose of CB 2679d increased factor IX activity half-life to 98.7 hours. The company says it has the potential to normalize FIX levels with daily or less frequent dosing.</li><li>Data on daily dosing of Orphan Drug-tagged CB 2679d should be available next quarter.</li><li>The company is collaborating with South Korea's ISU Abxis on development. Abxis uses the product name ISU304.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3253869-catalyst-bios-next-gen-hemophilia-candidate-cb-2679-isu304-cleared-begin-clinical-trials\" target=\"_blank\">Catalyst Bio's next gen hemophilia candidate CB 2679/ISU304 cleared to begin clinical trials in Korea; shares rocket 158%</a> (March 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317484\" data-linked=\"Catalyst Bio up 13% on positive Phase 1/2 data on hemophilia B candidate\" data-tweet=\"$CBIO - Catalyst Bio up 13% on positive Phase 1/2 data on hemophilia B candidate https://seekingalpha.com/news/3317484-catalyst-bio-up-13-on-positive-phase-1-2-data-on-hemophilia-b-candidate?source=tweet\" data-url=\"https://seekingalpha.com/news/3317484-catalyst-bio-up-13-on-positive-phase-1-2-data-on-hemophilia-b-candidate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317478\" data-ts=\"1513002746\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BURL\" target=\"_blank\">BURL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317478-cowen-sees-18-upside-on-burlington-stores\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cowen sees 18% upside on Burlington Stores</a></h4><ul> <li>Cowen <a href=\"https://twitter.com/CowenResearch/status/940179879525527553\" target=\"_blank\">reiterates</a> its Outperform rating on Burlington Stores (<a href='https://seekingalpha.com/symbol/BURL' title='Burlington Stores, Inc'>BURL</a> <font color='green'>+0.8%</font>).</li> <li>Analyst John Kernan takes an even stronger view on Burlington after factoring in benefits for the retailer from U.S. tax reform and the improving comparable sales trend.</li> <li>Kernan takes his price target on Burlington up to $132 to rep 18% upside potential.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317478\" data-linked=\"Cowen sees 18% upside on Burlington Stores\" data-tweet=\"$BURL - Cowen sees 18% upside on Burlington Stores https://seekingalpha.com/news/3317478-cowen-sees-18-upside-on-burlington-stores?source=tweet\" data-url=\"https://seekingalpha.com/news/3317478-cowen-sees-18-upside-on-burlington-stores\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317476\" data-ts=\"1513002401\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONCE\" target=\"_blank\">ONCE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317476-data-on-spark-therapeutics-hemophilia-candidate-spkminus-8011-lags-biomarins-valoctocogene\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Data on Spark Therapeutics&#39; hemophilia A candidate SPK-8011 lags BioMarin&#39;s valoctocogene roxaparvovec; shares down 32% premarket</a></h4><ul><li>Spark Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ONCE' title='Spark Therapeutics'>ONCE</a>) slumps&nbsp;<font color='red'>32%</font>&nbsp;premarket on increased volume while BioMarin Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/BMRN' title='BioMarin Pharmaceutical Inc.'>BMRN</a>) is up&nbsp;<font color='green'>7%</font>&nbsp;on light volume after both presented updated data on their respective gene therapy hemophilia A candidates at ASH in Atlanta.</li><li><a href=\"https://seekingalpha.com/pr/17022994-spark-therapeutics-presents-preliminary-data-investigational-spkminus-8011-phase-1-2-dose\" target=\"_blank\">Phase 1/2 results</a> on seven patients treated with Sparks' SPK-8011 showed a 100% reduction in (calculated) annualized bleeding rate &#40;ABR&#41; and zero (calculated) annualized bleeds (n=1, though). Annualized infusion rate &#40;AIR&#41;&nbsp;was reduced 98% to a mean of 1.2.</li><li><a href=\"https://seekingalpha.com/pr/17022681-biomarin-provides-1_5-years-clinical-data-valoctocogene-roxaparvovec-gene-therapy-severe\" target=\"_blank\">Phase 1/2 data</a> on BioMarin's valoctocogene roxaparvovec reduced both ABR and AIR to zero in six subjects.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317476\" data-linked=\"Data on Spark Therapeutics&#39; hemophilia A candidate SPK-8011 lags BioMarin&#39;s valoctocogene roxaparvovec; shares down 32% premarket\" data-tweet=\"$ONCE $ONCE $BMRN - Data on Spark Therapeutics&#39; hemophilia A candidate SPK-8011 lags BioMarin&#39;s valoctocogene roxaparvovec; shares down 32% premarket https://seekingalpha.com/news/3317476-data-on-spark-therapeutics-hemophilia-candidate-spkminus-8011-lags-biomarins-valoctocogene?source=tweet\" data-url=\"https://seekingalpha.com/news/3317476-data-on-spark-therapeutics-hemophilia-candidate-spkminus-8011-lags-biomarins-valoctocogene\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317473\" data-ts=\"1513001955\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LITE\" target=\"_blank\">LITE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317473-northland-capital-upgrades-lumentum\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Northland Capital upgrades Lumentum</a></h4><ul><li>        Northland Capital <a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20171211090501LITE\" target=\"_blank\">upgrades</a> Lumentum (NASDAQ:<a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a>) from Market Perform to Outperform.</li><li>               Latest analyst recommendations (via <a href=\"https://markets.ft.com/data/equities/tearsheet/forecasts?s=LITE:NSQ\" target=\"_blank\">FT</a>): 5 Buy, 4 Outperform, 5 Hold, and 1 Underperform.&nbsp;</li><li>               Median price target: $75. &nbsp;&nbsp;</li><li>               Lumentum shares are&nbsp;<font color='green'>up 3.8%</font>&nbsp;premarket. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3317473\" data-linked=\"Northland Capital upgrades Lumentum\" data-tweet=\"$LITE - Northland Capital upgrades Lumentum https://seekingalpha.com/news/3317473-northland-capital-upgrades-lumentum?source=tweet\" data-url=\"https://seekingalpha.com/news/3317473-northland-capital-upgrades-lumentum\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317472\" data-ts=\"1513001932\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTD\" target=\"_blank\">TTD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317472-trade-deskplus-3_9-suntrust-boosts-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">The Trade Desk +3.9% as SunTrust boosts to Buy</a></h4><ul>   <li>The Trade Desk (NASDAQ:<a href='https://seekingalpha.com/symbol/TTD' title='The Trade Desk'>TTD</a>) is <font color='green'>up 3.9%</font> premarket after an upgrade to Buy, as SunTrust joins other bulls on the stock.</li>    <li>It had more than a half-dozen Buy-equivalent ratings before SunTrust boosted it from Neutral.</li>    <li>Quotes this morning are indicating for the edge of $47/share, <font color='green'>up 161%</font> from the IPO price of 15 months ago.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317472\" data-linked=\"The Trade Desk +3.9% as SunTrust boosts to Buy\" data-tweet=\"$TTD - The Trade Desk +3.9% as SunTrust boosts to Buy https://seekingalpha.com/news/3317472-trade-deskplus-3_9-suntrust-boosts-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3317472-trade-deskplus-3_9-suntrust-boosts-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317470\" data-ts=\"1513001632\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317470-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/PZRX' title='PhaseRx'>PZRX</a> <font color='red'>-55%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17022958-phaserx-commences-voluntary-chapter-11-bankruptcy-protection-proceeding\" target=\"_blank\">commencing</a> voluntary chapter 11 bankruptcy protection proceeding.</li><li><a href='https://seekingalpha.com/symbol/SYRS' title='Syros Pharmaceuticals'>SYRS</a>&nbsp;<font color='red'>-48%</font>&nbsp;on its&nbsp;lead candidate <a href=\"https://seekingalpha.com/news/3317424-syros-pharmas-lead-candidate-fails-impress-mid-stage-blood-cancer-study-shares-48-percent\" target=\"_blank\">failing</a> to impress in mid-stage blood cancer study.</li><li><a href='https://seekingalpha.com/symbol/ONCE' title='Spark Therapeutics'>ONCE</a> <font color='red'>-32%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17022994-spark-therapeutics-presents-preliminary-data-investigational-spkminus-8011-phase-1-2-dose\" target=\"_blank\">reporting</a> preliminary data on SPK-8011 Phase 1/2 dose-escalation clinical trial.</li><li><a href='https://seekingalpha.com/symbol/GLBR' title='Global Brokerage, Inc.'>OTCPK:GLBR</a> <font color='red'>-29%</font>.</li><li><a href='https://seekingalpha.com/symbol/VTGN' title='VistaGen Therapeutics, Inc.'>VTGN</a> <font color='red'>-21%</font>.</li><li><a href='https://seekingalpha.com/symbol/GBT' title='Global Blood Therapeutics'>GBT</a>&nbsp;<font color='red'>-5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3317444-global-bloods-voxelotor-shows-positive-action-mid-stage-study-adolescents-sickle-cell-disease\" target=\"_blank\">announcing</a> new Phase 2a data for Voxelotor in adolescents with sickle cell disease.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3317470\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$PZRX $SYRS $ONCE - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3317470-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3317470-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317468\" data-ts=\"1513001370\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317468-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul> <a href='https://seekingalpha.com/symbol/BPMC' title='Blueprint Medicines'>BPMC</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/CHFS' title='CHF Solutions, Inc.'>CHFS</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/SNSS' title='Sunesis Pharmaceuticals, Inc.'>SNSS</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/ANTH' title='Anthera Pharmaceuticals, Inc.'>OTC:ANTH</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/BMRN' title='BioMarin Pharmaceutical Inc.'>BMRN</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/GLBS' title='Globus Maritime Ltd.'>GLBS</a> <font color='green'>+6%</font>.   </ul><div class=\"tiny-share-widget\" data-id=\"3317468\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$BPMC $CBIO $BLUE - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3317468-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3317468-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317467\" data-ts=\"1513001132\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPMC\" target=\"_blank\">BPMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317467-blueprints-avapritinib-shows-positive-effect-in-early-stage-mastocytosis-study-shares-up-25\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blueprint&#39;s avapritinib shows positive effect in early-stage mastocytosis study; shares up 25% premarket</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17022734-blueprint-medicines-announces-new-data-ongoing-phase-1-clinical-trial-avapritinib-bluminus\" target=\"_blank\">Updated data</a> from a Phase 1 clinical trial assessing Blueprint Medicines' (NASDAQ:<a href='https://seekingalpha.com/symbol/BPMC' title='Blueprint Medicines'>BPMC</a>) lead candidate avapritinib (formerly BLU-285) in patients with advanced systemic mastocytosis &#40;SM&#41; showed a treatment effect. The results were presented at ASH in Atlanta.</li><li>As of the October 4 cutoff date, the overall response rate was 72% (n=23/32) and the disease control rate (responders + those with stable disease) was 100% (n=32/32).</li><li>Most adverse events were mild or moderate with no discontinuations due to treatment. The most common Grade 3 (serious) adverse event was neutropenia (abnormally low neutrophils, a type of white blood cell).</li><li>The company plans to contact global regulatory authorities in H1 2018 to clarify pathways to approval in advanced SM and indolent and smoldering SM. A registration study in advanced SM should launch in H1 2018 followed by a proof-of-concept study in indolent and smoldering SM in H2 2018.</li><li><a href=\"http://www.blueprintmedicines.com/pipeline/\" target=\"_blank\">Avapritinib </a>is a highly selective inhibitor of the abnormally active receptor tyrosine kinase mutants KIT and PDGFR&alpha;, including KIT exon 17 and PDGFR&alpha;-D842V mutations which have no currently effective treatment options.</li><li>Shares are up&nbsp;<font color='green'>25%</font>&nbsp;premarket on average volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3311136-blueprints-bluminus-285-shows-positive-effect-early-stage-gist-study-phase-3-study-tap-h1\" target=\"_blank\">Blueprint's BLU-285 shows positive effect in early-stage GIST study; Phase 3 study on tap in H1 2018</a> (Nov. 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317467\" data-linked=\"Blueprint&#39;s avapritinib shows positive effect in early-stage mastocytosis study; shares up 25% premarket\" data-tweet=\"$BPMC - Blueprint&#39;s avapritinib shows positive effect in early-stage mastocytosis study; shares up 25% premarket https://seekingalpha.com/news/3317467-blueprints-avapritinib-shows-positive-effect-in-early-stage-mastocytosis-study-shares-up-25?source=tweet\" data-url=\"https://seekingalpha.com/news/3317467-blueprints-avapritinib-shows-positive-effect-in-early-stage-mastocytosis-study-shares-up-25\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317462\" data-ts=\"1513000710\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UTSI\" target=\"_blank\">UTSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317462-tonghao-discloses-active-stake-in-utstarcom\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tonghao discloses active stake in UTStarcom</a></h4><ul><li>        Tonghao (Cayman) Limited <a href=\"https://seekingalpha.com/filing/3793557\" target=\"_blank\">discloses</a> a 9.9% active stake in UTStarcom Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/UTSI' title='UTStarcom, Inc.'>UTSI</a>).</li><li>                  UTStarcom shares are&nbsp;<font color='green'>up 6.7%</font>&nbsp;premarket.&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3313546-utstarcom-five-year-high-product-sales-drive-profit-swing\" target=\"_blank\">UTStarcom to five-year high after product sales drive profit swing</a> (Nov. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317462\" data-linked=\"Tonghao discloses active stake in UTStarcom\" data-tweet=\"$UTSI - Tonghao discloses active stake in UTStarcom https://seekingalpha.com/news/3317462-tonghao-discloses-active-stake-in-utstarcom?source=tweet\" data-url=\"https://seekingalpha.com/news/3317462-tonghao-discloses-active-stake-in-utstarcom\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317460\" data-ts=\"1513000686\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVLCF\" target=\"_blank\">CVLCF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317460-riot-blockchains-tess-in-loi-to-go-public-shares-up-20\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Riot Blockchain&#39;s Tess in LOI to go public; shares up 20%</a></h4><ul><li>Tess' TessPay is a blockchain company which intends to develop TessPay Smart Contracts.</li><li>The company has inked an LOI to merge with Canada's Cresval Capital (<a href='https://seekingalpha.com/symbol/CVLCF' title='Cresval Capital Corp.'>OTC:CVLCF</a>). For consideration, TessPay will be issued 80M shares of Cresval. As 52% owner of TessPay, Riot (NASDAQ:<a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>) will receive 41.6M of those shares.</li><li>Assuming a definitive agreement can be reached, a close by the end of Q2 is expected.</li><li>This would be the first of Riot's investments to become a stand-alone public company.</li><li>RIOT&nbsp;<font color='green'>+20.55%</font>&nbsp;premarket</li><li>Source: <a href=\"https://seekingalpha.com/pr/17023141-b-riot-b-blockchains-tesspay-signs-letter-intent-merger-publically-traded-cresval-capital\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3317460\" data-linked=\"Riot Blockchain&#39;s Tess in LOI to go public; shares up 20%\" data-tweet=\"$CVLCF $CVLCF $RIOT - Riot Blockchain&#39;s Tess in LOI to go public; shares up 20% https://seekingalpha.com/news/3317460-riot-blockchains-tess-in-loi-to-go-public-shares-up-20?source=tweet\" data-url=\"https://seekingalpha.com/news/3317460-riot-blockchains-tess-in-loi-to-go-public-shares-up-20\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317456\" data-ts=\"1513000052\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GDDY\" target=\"_blank\">GDDY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317456-capital-international-investors-discloses-godaddy-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Capital International Investors discloses GoDaddy stake</a></h4><ul><li>        Capital International Investors <a href=\"https://seekingalpha.com/filing/3794023\" target=\"_blank\">discloses</a> a 10.9% stake in GoDaddy (NYSE:<a href='https://seekingalpha.com/symbol/GDDY' title='GoDaddy Inc.'>GDDY</a>).</li><li>               GoDaddy shares are&nbsp;<font color='green'>up 0.5%</font>&nbsp;premarket.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317209-wedbush-initiates-godaddy\" target=\"_blank\">Wedbush initiates GoDaddy</a> (Dec. 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317456\" data-linked=\"Capital International Investors discloses GoDaddy stake\" data-tweet=\"$GDDY - Capital International Investors discloses GoDaddy stake https://seekingalpha.com/news/3317456-capital-international-investors-discloses-godaddy-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3317456-capital-international-investors-discloses-godaddy-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317452\" data-ts=\"1512999977\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARGX\" target=\"_blank\">ARGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317452-argenxs-efgartigimod-shows-treatment-effect-in-mid-stage-mg-study-shares-ahead-25-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Argenx&#39;s efgartigimod shows treatment effect in mid-stage MG study; shares ahead 25% premarket</a></h4><ul><li>Belgian biotech argenx (NASDAQ:<a href='https://seekingalpha.com/symbol/ARGX' title='Argenx SE'>ARGX</a>) is up&nbsp;<font color='green'>25%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/17022785-argenx-reports-positive-topline-results-phase-2-proof-concept-trial-argxminus-113\" target=\"_blank\">announcement </a>of positive data from a Phase 2 proof-of-concept study assessing ARGX-113 (efgartigimod) in patients with <a href=\"http://www.myasthenia.org/WhatisMG.aspx\" target=\"_blank\">myasthenia gravis</a> &#40;MG&#41;, an autoimmune neuromuscular disorder characterized by weakness in the voluntary muscles.</li><li>The results showed a clinically meaningful and statistically significant treatment benefit over placebo in 24 subjects. 75% of participants experienced statistically valid increases in MG-ADL scores for at least six consecutive weeks compared to 25% for placebo (p=0.0391). Separation from placebo was observed one week after the first infusion.</li><li>No serious safety signals were observed.</li><li>Complete results will be presented at the American Academy of Neurology Annual Meeting in April 2018.</li><li><a href=\"http://www.argenx.com/en-GB/content/argx-113/22/\" target=\"_blank\">Efgartigimod </a>is an antibody fragment designed to block antibody recycling through a receptor called FcRn which induces rapid depletion of autoimmune disease-causing IgG autoantibodies.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317452\" data-linked=\"Argenx&#39;s efgartigimod shows treatment effect in mid-stage MG study; shares ahead 25% premarket\" data-tweet=\"$ARGX - Argenx&#39;s efgartigimod shows treatment effect in mid-stage MG study; shares ahead 25% premarket https://seekingalpha.com/news/3317452-argenxs-efgartigimod-shows-treatment-effect-in-mid-stage-mg-study-shares-ahead-25-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3317452-argenxs-efgartigimod-shows-treatment-effect-in-mid-stage-mg-study-shares-ahead-25-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317451\" data-ts=\"1512999554\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IONS\" target=\"_blank\">IONS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317451-ionis-pharmaceuticals-licenses-ionis-htt-rx-to-roche-following-successful-phase-1-2a-study-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ionis Pharmaceuticals licenses IONIS-HTT Rx to Roche following successful Phase 1/2a study in patients with HD</a></h4><ul><li>Ionis Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/IONS' title='Ionis Pharmaceuticals, Inc.'>IONS</a>) <a href=\"https://seekingalpha.com/pr/17022930-ionis-pharmaceuticals-licenses-ionis-htt-rx-partner-following-successful-phase-1-2a-study\" target=\"_blank\">announces</a> that Roche (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a>) has exercised its option to license IONIS-HTT<sub>Rx</sub> following the completion of a Phase 1/2a study of IONIS-HTT<sub>Rx</sub> in people with <a href=\"https://en.wikipedia.org/wiki/Huntington%27s_disease\" target=\"_blank\">Huntington's disease</a>.</li><li>Roche will now be responsible for all development and commercial activities. In conjunction with the decision to license IONIS-HTT<sub>Rx</sub>, Ionis earned a $45M license fee from Roche.</li><li>Shares of Ionis are up&nbsp;<font color='green'>3%</font>&nbsp;premarket on light volume.</li>                   </ul><div class=\"tiny-share-widget\" data-id=\"3317451\" data-linked=\"Ionis Pharmaceuticals licenses IONIS-HTT Rx to Roche following successful Phase 1/2a study in patients with HD\" data-tweet=\"$IONS $IONS $RHHBY - Ionis Pharmaceuticals licenses IONIS-HTT Rx to Roche following successful Phase 1/2a study in patients with HD https://seekingalpha.com/news/3317451-ionis-pharmaceuticals-licenses-ionis-htt-rx-to-roche-following-successful-phase-1-2a-study-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3317451-ionis-pharmaceuticals-licenses-ionis-htt-rx-to-roche-following-successful-phase-1-2a-study-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317449\" data-ts=\"1512999391\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NXPI\" target=\"_blank\">NXPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317449-activist-investor-says-nxp-semiconductors-worth-qualcomm-offer-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Activist investor says NXP Semiconductors worth more than Qualcomm offer (update)</a></h4><ul>     <li>Activist investor Elliott Advisors thinks NXP Semiconductors (NASDAQ:<a href='https://seekingalpha.com/symbol/NXPI' title='NXP Semiconductors'>NXPI</a>) is worth <a href=\"https://seekingalpha.com/pr/17023093-elliott-believes-nxp-semiconductors-worth-135-per-share-standalone-basis\" target=\"_blank\">$135 per share</a>.</li>     <li>Elliott outlines its case in a letter to shareholders and a presentation.</li>     <li>The investor says Qualcomm&rsquo;s (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>) &ldquo;highly opportunistic&rdquo; $110 per share acquisition offer is &ldquo;acting as a ceiling on NXP&rsquo;s valuation.&rdquo;</li>     <li>Qualcomm&rsquo;s acquisition of NXP was delayed due to regulatory concerns from antitrust officials. Broadcom, which has made an unsolicited offer on Qualcomm, would prefer for the company to back away from NXP.</li>     <li>NXP shares are&nbsp;<font color='green'>up 0.88%&nbsp;</font>premarket.</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3313376-step-forward-qualcomm-nxp-deal\" target=\"_blank\">Step forward for Qualcomm-NXP deal</a> (Nov. 19)</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3314263-broadcom-interfere-qualcomms-nxp-bid\" target=\"_blank\">Broadcom could interfere with Qualcomm's NXP bid</a> (Nov. 24)</li>     <li>Update: Qualcomm <a href=\"https://www.qualcomm.com/news/releases/2017/12/11/qualcomm-responds-elliott-regarding-nxp\" target=\"_blank\">issues </a>a statement:&nbsp;&ldquo;Elliott&rsquo;s value assertion for NXP is unsupportable and is clearly nothing more than an attempt to advance its own self-serving agenda. We remain fully committed to closing the acquisition of NXP and believe that the agreed-upon price of $110 is full and fair.&rdquo;</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317449\" data-linked=\"Activist investor says NXP Semiconductors worth more than Qualcomm offer (update)\" data-tweet=\"$NXPI $NXPI $QCOM - Activist investor says NXP Semiconductors worth more than Qualcomm offer (update) https://seekingalpha.com/news/3317449-activist-investor-says-nxp-semiconductors-worth-qualcomm-offer-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3317449-activist-investor-says-nxp-semiconductors-worth-qualcomm-offer-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>85&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317445\" data-ts=\"1512998588\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OSTK\" target=\"_blank\">OSTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317445-investors-bid-up-overstock-com\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors bid up Overstock.com</a></h4><ul> <li>Overstock.com (NASDAQ:<a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a>) jumps in early trading after Morgan Stanley reports a passive stake of 11.4% in the e-commerce player.</li> <li>The stock has also landed on more lists of potential Bitcoin/blockchain plays.</li> <li>OSTK <font color='green'>+10.26%</font> premarket to $49.70. The 52-week high on Overstock is $65.70.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317445\" data-linked=\"Investors bid up Overstock.com\" data-tweet=\"$OSTK - Investors bid up Overstock.com https://seekingalpha.com/news/3317445-investors-bid-up-overstock-com?source=tweet\" data-url=\"https://seekingalpha.com/news/3317445-investors-bid-up-overstock-com\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317444\" data-ts=\"1512998453\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBT\" target=\"_blank\">GBT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317444-global-bloods-voxelotor-shows-positive-action-in-mid-stage-study-in-adolescents-sickle-cell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Global Blood&#39;s voxelotor shows positive action in mid-stage study in adolescents with sickle cell disease, two deaths in compassionate use study pressures shares, down 10%</a></h4><ul><li>Global Blood Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/GBT' title='Global Blood Therapeutics'>GBT</a>) slips&nbsp;<font color='red'>10%</font>&nbsp;premarket on increased volume despite positive <a href=\"https://seekingalpha.com/pr/17022696-gbt-announces-new-phase-2a-data-ash-voxelotor-adolescents-sickle-cell-disease-scd\" target=\"_blank\">mid-stage data</a> on lead candidate voxelotor (GBT440) in adolescents (aged 12 - 17) with sickle cell disease &#40;SCD&#41;. The results are being presented today at ASH in Atlanta.</li><li>Interim data from the study, HOPE-KIDS 1, showed treatment with voxelotor increased hemoglobin levels at least 1 g/dL in 55% (n=6/11) of participants. The results were consistent with those observed in adults. On the safety front, voxelotor showed a favorable tolerability profile.</li><li>Results from a compassionate access case study in seven patients with severe SCD showed all experienced increases in hemoglobin values, including 71% (n=5/7) at least 1 g/dL. The number of transfusions decreased 60% during the 24-week treatment period.</li><li><a href=\"https://seekingalpha.com/pr/17022931-gbt-announces-presentation-six-studies-ash-supporting-voxelotor-sickle-cell-disease-scd\" target=\"_blank\">Two patients died</a> while receiving voxelotor but neither was considered related to treatment. Both had multiple comorbidities and advanced organ injury prior receiving the drug.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317444\" data-linked=\"Global Blood&#39;s voxelotor shows positive action in mid-stage study in adolescents with sickle cell disease, two deaths in compassionate use study pressures shares, down 10%\" data-tweet=\"$GBT - Global Blood&#39;s voxelotor shows positive action in mid-stage study in adolescents with sickle cell disease, two deaths in compassionate use study pressures shares, down 10% https://seekingalpha.com/news/3317444-global-bloods-voxelotor-shows-positive-action-in-mid-stage-study-in-adolescents-sickle-cell?source=tweet\" data-url=\"https://seekingalpha.com/news/3317444-global-bloods-voxelotor-shows-positive-action-in-mid-stage-study-in-adolescents-sickle-cell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317441\" data-ts=\"1512997989\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIT\" target=\"_blank\">FIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317441-fitbit-and-jawbone-resolve-litigation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fitbit and Jawbone resolve litigation</a></h4><ul><li>        Fitbit (NYSE:<a href='https://seekingalpha.com/symbol/FIT' title='Fitbit, Inc.'>FIT</a>) and Jawbone announce resolving all outstanding litigation between the companies.</li><li>                  The terms of the agreement were not disclosed.    </li><li>               The legal battles between the wearable companies started in May 2015 with Jawbone&rsquo;s accusation that Fitbit hired away employees and took critical IP.&nbsp;</li><li>               Fitbit shares are<font color='green'> up 1.3%</font>&nbsp;premarket. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3317441\" data-linked=\"Fitbit and Jawbone resolve litigation\" data-tweet=\"$FIT - Fitbit and Jawbone resolve litigation https://seekingalpha.com/news/3317441-fitbit-and-jawbone-resolve-litigation?source=tweet\" data-url=\"https://seekingalpha.com/news/3317441-fitbit-and-jawbone-resolve-litigation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317424\" data-ts=\"1512996782\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYRS\" target=\"_blank\">SYRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317424-syros-pharmas-lead-candidate-fails-to-impress-in-mid-stage-blood-cancer-study-shares-down-48\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Syros Pharma&#39;s lead candidate fails to impress in mid-stage blood cancer study; shares down 48% premarket</a></h4><ul><li>Thinly traded micro cap Syros Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SYRS' title='Syros Pharmaceuticals'>SYRS</a>) slumps&nbsp;<font color='red'>48%</font>&nbsp;premarket on increased volume in response to <a href=\"https://seekingalpha.com/pr/17022745-syros-announces-initial-clinical-data-ongoing-phase-2-trial-syminus-1425-showing-biological\" target=\"_blank\">preliminary data</a> from a Phase 2 clinical trial assessing lead candidate SY-1425 (tamibarotene) in patients with acute myeloid leukemia &#40;AML&#41; and myelodysplastic syndrome &#40;MDS&#41;. The results were presented as ASH in Atlanta, GA.</li><li>Out of 48 evaluable patients (23 with AML and 25 with MDS), there was only one complete responder. 10 AML and two MDS patients showed \"evidence of clinical activity.\"</li><li>On the safety front, most adverse events (AEs) were mild or moderate. The most common Grade 3 (serious) or Grade 4 (life-threatening) AE was abnormally high blood triglycerides (16%).</li><li>Development is ongoing.</li><li>Tamibarotene is a selective retinoic acid receptor alpha agonist.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317424\" data-linked=\"Syros Pharma&#39;s lead candidate fails to impress in mid-stage blood cancer study; shares down 48% premarket\" data-tweet=\"$SYRS - Syros Pharma&#39;s lead candidate fails to impress in mid-stage blood cancer study; shares down 48% premarket https://seekingalpha.com/news/3317424-syros-pharmas-lead-candidate-fails-to-impress-in-mid-stage-blood-cancer-study-shares-down-48?source=tweet\" data-url=\"https://seekingalpha.com/news/3317424-syros-pharmas-lead-candidate-fails-to-impress-in-mid-stage-blood-cancer-study-shares-down-48\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317426\" data-ts=\"1512996640\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSIQ\" target=\"_blank\">CSIQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317426-canadian-solar-ceo-seeks-to-take-company-private\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canadian Solar CEO seeks to take company private</a></h4><ul>     <li>Canadian Solar (NASDAQ:<a href='https://seekingalpha.com/symbol/CSIQ' title='Canadian Solar Inc.'>CSIQ</a>) <font color='green'>+5%</font> premarket after announcing it received a letter from CEO and top shareholder Shawn Qu to <a href=\"https://seekingalpha.com/pr/17022920-canadian-solar-inc-announces-receipt-preliminary-non-binding-going-private-proposal-letter\" target=\"_blank\">take the company private</a>.</li>     <li>Qu and his wife are offering to buy all outstanding shares they do not already own for $18.47/share, representing a 7.1% premium to CSIQ's Friday closing price; the pair <a href=\"https://www.reuters.com/article/us-canadian-solar-m-a/canadian-solar-ceo-offers-to-take-company-private-idUSKBN1E51BK\" target=\"_blank\">owns ~23.5% of the shares</a>.</li>     <li>CSIQ says its board has formed a special committee to consider the proposal.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317426\" data-linked=\"Canadian Solar CEO seeks to take company private\" data-tweet=\"$CSIQ - Canadian Solar CEO seeks to take company private https://seekingalpha.com/news/3317426-canadian-solar-ceo-seeks-to-take-company-private?source=tweet\" data-url=\"https://seekingalpha.com/news/3317426-canadian-solar-ceo-seeks-to-take-company-private\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317421\" data-ts=\"1512996208\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FSLR\" target=\"_blank\">FSLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317421-first-solar-sunpower-upgraded-baird-sees-solar-market-inflection-point\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">First Solar, SunPower upgraded as Baird sees solar market at inflection point</a></h4><ul>     <li>First Solar (NASDAQ:<a href='https://seekingalpha.com/symbol/FSLR' title='First Solar, Inc.'>FSLR</a>) <font color='green'>+2.5%</font> premarket after Baird <a href=\"https://www.streetinsider.com/Analyst+Comments/Baird+Upgrades+First+Solar+%28FSLR%29+to+Outperform%2C+Named+Top+Pick+in+Sold+Sector/13586210.html\" target=\"_blank\">upgrades</a> shares to Outperform from Neutral with a Street-high $82 price target, raised from $69, with the firm calling it the top pick within the solar sector.</li>     <li>Analyst Ben Kallo note says Baird recently met with FSLR&rsquo;s management and sees the company as well positioned for growth; Series 6 has some execution risk, but Baird sees shares appreciating near-term.</li>     <li>Baird also <a href=\"https://www.streetinsider.com/Analyst+Comments/Baird+Upgrades+SunPower+%28SPWR%29+to+Outperform+Noting+Sentiment+Should+Continue+To+Improve/13586224.html\" target=\"_blank\">boosts</a> SunPower (NASDAQ:<a href='https://seekingalpha.com/symbol/SPWR' title='SunPower Corporation'>SPWR</a>) to Outperform from Neutral with a $10 price target, hiked from $7, saying sentiment should improve as SPWR ramps P series production and strengthens its balance sheet; shares <font color='green'>+5.5%</font> premarket.</li>     <li>The firm thinks potential headwinds from the Suniva petition mostly are priced in, and shares could benefit if no tariff is enacted or SPWR receives an exemption.</li>     <li>Baird believes the solar market has hit an inflection point that will continue to see long-term growth driven by falling installation costs and technological advancement.</li>     <li>ETFs: <a href='https://seekingalpha.com/symbol/TAN' title='Invesco Solar Portfolio ETF'>TAN</a>, <a href='https://seekingalpha.com/symbol/KWT' title='VanEck Vectors Solar Energy ETF'>KWT</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3317421\" data-linked=\"First Solar, SunPower upgraded as Baird sees solar market at inflection point\" data-tweet=\"$FSLR $FSLR $SPWR - First Solar, SunPower upgraded as Baird sees solar market at inflection point https://seekingalpha.com/news/3317421-first-solar-sunpower-upgraded-baird-sees-solar-market-inflection-point?source=tweet\" data-url=\"https://seekingalpha.com/news/3317421-first-solar-sunpower-upgraded-baird-sees-solar-market-inflection-point\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317417\" data-ts=\"1512995780\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSTM\" target=\"_blank\">VSTM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317417-verastem-to-file-u-s-marketing-application-for-duvelisib-next-quarter-shares-up-22-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verastem to file U.S. marketing application for duvelisib next quarter; shares up 22% premarket</a></h4><ul><li>Verastem (NASDAQ:<a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a>) is up&nbsp;<font color='green'>22%</font>&nbsp;premarket on increased volume on the heels of its <a href=\"https://seekingalpha.com/pr/17022759-verastem-announces-clinical-data-pivotal-phase-3-duo-study-duvelisib-significantly-improves\" target=\"_blank\">announcement </a>that it plans to submit a New Drug Application &#40;NDA&#41; to the FDA next quarter seeking full approval for lead candidate duvelisib in relapsed/refractory chronic lymphocytic leukemia &#40;CLL&#41;/small lymphocytic lymphoma &#40;SLL&#41; and accelerated approval for relapsed/refractory follicular lymphoma &#40;FL&#41;.</li><li>The data supporting the application were generated in the Phase DUO study and Phase 2 DYNAMO.</li><li>Duvelisib is a dual inhibitor of two enzymes called phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma. Both are associated with the growth and survival of malignant B cells and T cells.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3293761-verastems-duvelisib-successful-late-stage-blood-cancer-study-shares-ahead-30-percent\" target=\"_blank\">Verastem's duvelisib successful in late-stage blood cancer study; shares ahead 30% premarket</a> (Sept. 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317417\" data-linked=\"Verastem to file U.S. marketing application for duvelisib next quarter; shares up 22% premarket\" data-tweet=\"$VSTM - Verastem to file U.S. marketing application for duvelisib next quarter; shares up 22% premarket https://seekingalpha.com/news/3317417-verastem-to-file-u-s-marketing-application-for-duvelisib-next-quarter-shares-up-22-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3317417-verastem-to-file-u-s-marketing-application-for-duvelisib-next-quarter-shares-up-22-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317409\" data-ts=\"1512994376\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLUE\" target=\"_blank\">BLUE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317409-bluebirds-bb2121-shows-94-response-rate-in-early-stage-multiple-myeloma-study-shares-up-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bluebird&#39;s bb2121 shows 94% response rate in early-stage multiple myeloma study; shares up 5% premarket</a></h4><ul><li>Bluebird bio (NASDAQ:<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a>) is up<font color='green'> 5%</font>&nbsp;premarket, albeit on only 193 shares, on the heels of its <a href=\"https://seekingalpha.com/pr/17022749-celgene-corporation-bluebird-bio-announce-updated-results-ongoing-multicenter-phase-1-study\" target=\"_blank\">announcement</a> of updated data from a Phase 1 clinical trial assessing CAR-T candidate bb2121 in patients with late-stage relapsed/refractory multiple myeloma &#40;MM&#41;.</li><li>Study participants were heavily pretreated, having received a median of seven prior lines of therapy.</li><li>In 18 patients in the active dose cohorts (median follow-up of 40 weeks), the objective response rate was 94% (n=17/18), including 7 complete responders and 16 considered at least very good partial responders. Median progression-free survival has not been reached.</li><li>In the dose-escalation phase, 71% (n=15/21) experienced cytokine release syndrome &#40;CRS&#41;, mostly Grade 1 (mild) or Grade 2 (moderate). Two patients (9%) experienced Grade 3 (severe) CRS. Two deaths were reported, one from cardiac arrest and one from myelodysplastic syndrome.</li><li>Development partner Celgene (NASDAQ:<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a>) is&nbsp;<font color='green'>3%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317409\" data-linked=\"Bluebird&#39;s bb2121 shows 94% response rate in early-stage multiple myeloma study; shares up 5% premarket\" data-tweet=\"$BLUE $BLUE $CELG - Bluebird&#39;s bb2121 shows 94% response rate in early-stage multiple myeloma study; shares up 5% premarket https://seekingalpha.com/news/3317409-bluebirds-bb2121-shows-94-response-rate-in-early-stage-multiple-myeloma-study-shares-up-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3317409-bluebirds-bb2121-shows-94-response-rate-in-early-stage-multiple-myeloma-study-shares-up-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":74,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}